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Abstract 
Part-1: Bone morphogenetic protein-7 release from endogenous neural 
precursor cells suppresses the tumorigenicity of glioma stem cells.  
Gliomas cells with stem-like properties (GSCs) control tumor growth and 
recurrence. Here, I showed that endogenous neural precursor cells (NPCs) perform 
an anti-tumor response by specifically targeting GSCs: In vitro, NPCs 
predominantly expressed BMP7; BMP7 was constitutively released from 
neurospheres and induced canonical BMP-signaling in GSCs. Exposure of human 
and murine GSCs to neurosphere-derived BMP7 increased GSC differentiation, 
attenuated GSC-marker expression, GSC self-renewal and the ability for tumor 
initiation. NPC-derived BMP or recombinant BMP7 reduced glioma expansion 
from GSCs. This anti-tumor response of NPCs protect the brain from gliomas by 
releasing BMP7, which acts as a paracrine tumor suppressor that represses 
proliferation, self-renewal and tumor-initiation of GSCs.   
Part-2: Transferrin-receptor-mediated iron accumulation controls 
proliferation and glutamate release in glioma cells 
Transferrin receptors (TfR) are overexpressed in brain tumors, but the pathological 
relevance has not been fully explored. Here, I showed that TfR is an important 
downstream effector of ets transcription factors that promotes glioma proliferation 
and increases glioma-evoked neuronal death. TfR mediates iron accumulation and 
reactive oxygen formation and thereby enhanced proliferation in clonal human 
glioma lines, as shown by the following experiments: (1) downregulating TfR 
expression reduced proliferation in vitro and in vivo; (2) forced TfR expression in 
low-grade glioma accelerated proliferation to the level of high-grade glioma; (3) 
iron and oxidant chelators attenuated tumor proliferation in vitro and tumor size in 
vivo. TfR-induced oxidant accumulation modified cellular signaling by 
inactivating a protein tyrosine phosphatase (low-molecular-weight protein tyrosine 
phosphatase), activating mitogen-activated protein kinase and Akt and by 
inactivating p21/cdkn1a and pRB. Inactivation of these cell cycle regulators 
facilitated S-phase entry. Besides its effect on proliferation, TfR also boosted 
glutamate release, which caused N-methyl-D-aspartate-receptor-mediated reduction 
of neuron cell mass. Overall my results indicate that TfR promotes glioma 
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progression by two mechanisms, an increase in proliferation rate and glutamate 
production, the latter mechanism providing space for the progressing tumor mass. 
 
 
Key words: 
Glioma stem cells, BMP-7, Transferrin receptor, Ets, Reactive oxygen species.
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1. Introduction 
 
1.1. Brain tumors and their classification 
Glia cells are the most common cell type in the brain and make up 90 % of the 
total cell number (Kettenmann, H et al, 1995) depending on species. They were 
discovered by Virchow (1856), who described them as Nervenkitt, a kind of glue 
for neurons (gr. glia: glue). Initially, they were considered as merely supporting 
cells for neurons, yet recently they were shown to fulfill a range of far more 
complex functions. The group of glia cells consists of astrocytes, oligodendrocytes 
and Schwann cells (Kettenmann, H et al, 1995).  Historically, brain tumors were 
thought to consist of transformed glia cells and are therefore called gliomas. 
Different types of gliomas are astrocytomas, oligodendrogliomas and 
schwannomas, depending on the preferential type of differentiation of these 
tumors. Schwannomas often correspond to benign tumors. It is still unknown how 
these transformations occur and what triggers them. One theory claims that 
disruptions in the glial cell cycle lead to glioma formation. However, recent 
research provided more and more evidence that gliomas emerge from neural 
precursor cells.  
Gliomas are the most common group of primary tumors in the brain and make up  
30 – 40 % of all brain tumors (Kleihues, P et al, 1993). The World Health 
Organisation (WHO) introduced a classification in 1993, which divides 
astrocytomas into four malignancy grades:  
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Tab. 1.1.  The World Health Organization (WHO) grading system for astrocytomas 
Grade Example Criteria 
WHO I 
 
 
Pilocytic astrocytoma 
Myxopapillary 
Ependymoma/Subendymoma 
Low proliferating,  
discrete, 
non invasive tumor 
WHO II Diffuse astrocytoma  
Papillary, cellular and clear cell 
Ependymoma 
Modest proliferating,  
partly invasive tumor 
WHO III Anaplastic astrocytoma 
Anaplastic ependymoma 
Fast proliferating,  
invasive tumor 
WHO IV Glioblastoma multiforme  
Highly malignant glioma-like 
Pineoblastoma and Medulloblastoma 
Rapidly proliferating,  
highly invasive tumor 
 
 
In the present work research and conclusions will be restricted to cells representing 
glioblastoma multiforme (GBM) or glioma, i.e. a grade IV brain tumor.  
 
1.2. Epidemiology of gliomas 
Gliomas or glioblastomas occur with an incidence of 5 in 100,000 (Friese, M.A.et 
al, 2004). The peak of onset of glioblastomas is around 50 - 55 years, which makes 
them a strongly age-related pathology. Men are slightly more prone to these 
neoplasms. Furthermore, the incidence is 2 - 3 times higher in white than in black 
people. Prognosis is poor and the median survival has remained at 9 to 12 months 
for decades (Stupp, R et al, 2005), only few patients survive for three or more 
years. Main risk factors are high dose radiation, hereditary syndromes and 
increasing age. Although the last years have revealed some major approaches to 
develop new surgical and radiation techniques as well as multiple antineoplastic 
drugs, a cure for glioblastoma remains elusive (DeAngelis, L.M. et al, 2001). 
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1.3. Diagnosis and treatment of gliomas 
 
 
 
Fig. 1.3.  MRT of a human brain, revealing a glioblastoma multiforme 
(rad.usuhs.mil/rad/who/zs224248) 
 
If a neurological examination points to a brain tumor, additional testings will be 
made. These mainly include scans like magnetic resonance imaging (MRI, Fig. 
1.3.), computer tomography (CT) or positron emission tomography (PET). In most 
cases therapy starts with surgical removal of the tumor. Since for the tumor patient 
gliomas may be located in brain areas which are of vital importance and the 
surgical removal of these neoplasms can be much more difficult than removing a 
tumor in other parts of the body. Even if the surgery is successful it has to be 
assumed that tumor cells have already spread throughout the brain and may be the 
source for tumor relapses. 
One of the main properties of glioma cells is their invasive behaviour, which also 
signifies the biggest challenge regarding therapy (Holland, E.C. et al, 2001; 
Kleihues, P et al, 1995). Therefore combined radiochemotherapy typically follows 
surgery. Conventional radiation therapy uses X- or gamma-rays but also other 
types of radiation are available. At present, the standard chemotherapeutic is 
temozolomide (Temodal®). Its cytotoxicity is due to alcylation of the nucleobase 
guanine. Although many efforts have been made during the last years to improve 
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the existing therapies, the biggest problem is still the extreme invasive nature of 
glioblastomas. It is virtually impossible to prevent migration of tumor cells into the 
adjacent brain tissue, which may be the primary cause for relapses.  
 
1.4. Pathophysiology of gliomas 
Glioma or Glioblastoma multiforme (GBM) consist of a heterogenous mixture of 
poorly differentiated neoplastic astrocytes (Holland, E.C.et al, 2001). They can 
occur as primary, which means de novo tumors but can also, although less 
frequent, develop from lower grade astrocytomas and thus are defined as 
secondary tumors. The latter typically develop in younger patients (< 45 years) 
whereas de novo tumors arise almost solely in elderly patients (around 65 years). 
The tumor as such forms a solid mass from which neoplastic cells are 
disseminating into the adjacent brain tissue. The tumor itself can reach a 
considerable size and squeeze out larger amounts of brain mass (Fig. 1.4.), which 
usually leads to diverse neurological defects.  
 
 
 
Fig. 1.4. Macroscopic view of glioblastoma multiforme in a human brain  
(www.neuropat.dote.hu/jpeg/tumor/3gliobl1). 
Although primary and secondary tumors differ on the genetic level in many ways, 
there are some common genetic abnormalities, which are considered as hallmarks 
of glioblastomas. One of them is the loss of heterozygosity (LOH) on chromosome 
10, which seems to be specific for grade IV brain tumors. Very well known are 
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mutations in the tumor suppressor gene p53 on chromosome 9, which also plays a 
pivotal role in other types of cancer. In fact, only about a third of glioblastomas 
carries this mutation, which corresponds to the percentage in lower grade gliomas. 
However, recent reports indicated that p53 mutations may be much more common, 
and these mutations can be very complex and may have been overlooked ( Zheng, 
H et al, 2008). This suggests that the p53 gene is involved rather early in 
neoplastic transformation (Kleihues, P., et al, 1993). In about one third of all 
GBMs one can find amplification and mutation of the endothelial growth factor 
receptor gene (EGFR) like EGFRvIII which is the mutant version of EGFR in 
Glioblastoma multiforme mutation which leads to increased cell proliferation. 
Furthermore platelet-derived growth factor alpha (PDGF-α) and phosphatase and 
tensin homolog deleted on chromosome ten (PTEN) are two more genes, of which 
the expression is altered in GBMs (Knobbe,C.B. et al, 2002; Nakamura, J.L. et al, 
2007).  PDGF-α belongs to the family of growth factors and is involved in the 
regulation of cell growth and cell division. It plays a particular role in 
angiogenesis, which is characteristically increased in cancer to provide sufficient 
nutrition supply for the tumor. The phosphatase PTEN is a tumor suppressor, 
which is related to a variety of biological functions like apoptosis, inflammation 
and immunity. These genetic defects have an effect on other cell proteins and 
finally result in tumor formation.  
 
1.5. Cell of origin of gliomas 
The identification of the cellular origin of gliomas presents an opportunity for 
improving our understanding of this disease. Recent work in both animal and 
primary gliomas suggests the more likely possibility that malignant gliomas arise 
from neural proginator cells. Overexpressing oncogenic Ras and Akt in progenitor 
cells results in mouse brain tumors that are histologically similar to their human 
counterparts, but targeting more mature astrocytic progenitors is not equally 
oncogenic (Holland, E.C. et al 2000). Targeting platelet-derived growth factor 
(PDGF)-B expression to progenitor cells results in tumors identical to human 
oligodendrogliomas (Dai, C et al 2001). In addition, oncogenic events such as 
CDNK2A/p16 deletion can drive more mature astrocytic cells to cells that have a 
progenitor phenotype, with multipotent differentiation potential (Bachoo, R.M. et 
al 2002). Furthermore, malignant gliomas likely contain tumor stem cells, a 
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relatively primitive population responsible for populating and repopulating the 
tumors as they develop and progress (Galli, R., et al 2004, Singh, S.K., et al, 2004 
and 2003, ); such tumor stem cells may be transformed variants of normal neural 
progenitor cells. The existence of these tumor stem cells may have major 
therapeutic implications as well because therapies that do not ablate the tumor stem 
cells will ultimately prove ineffective in eradicating the tumor. 
 
Fig. 1.5: Mutations in stem cells and/or progenitor cells might give rise to glioma stem cells. 
The cancer stem cell might appear after mutations in specific stem cells or early stem cell 
progenitors. It is also possible that cancer stem cells can be derived from differentiated cells. There 
might be numerous factors in the host microenvironment that trigger the initial steps of tumor 
formation. (Modified from Bjerkvig R, et al, 2005).   
 
1.6. Glioma Stem cells (GSCs) 
In the past few years, stem cell-like tumor cells have been identified in gliomas 
(Singh, S.K et al 2004). They have been consecutively termed glioma stem cells, 
brain tumor stem cells or brain tumor initiating cells and identification of these 
cells has created a paradigm shift in brain tumor research. They are characterized 
by unlimited capacity for self-renewal, high proliferation, increased ability for 
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tumor initiation, multi-differentiation and expression of stem cell markers such as 
CD133 (prominin-1) and nestin. CD133 is a cell membrane glycoprotein and 
nestin is an intermediate filament protein that is produced in stem/progenitor cells 
during development and is a marker of proliferating and migrating cells. CD133 
and nestin are currently the most accredited markers for the identification of neural 
stem cells. Their use in glioma stem cell research has been fundamental to reveal 
the biological properties of glioma stem cells, such as tumor progression and 
resistance to ionizing radiation or chemotherapy. As a new concept for brain tumor 
therapy it may be useful to target these CD133 positive glioma stem cells.  
 
1.7. Glioma stem cells may represent as novel therapeutic targets 
Current chemotherapeutic strategies involve using non-specific cytotoxic agents 
that target rapidly cycling cells. Although this may reduce disease burden in many 
cases, these therapies may miss the rare, self-renewing population that truly gives 
rise to the malignancy (GSCs) and which is usually non-responsive to standard 
chemotherapy (Lu C et al, 2008) Dissecting the molecular mechanisms that 
underlie the ability of these cells to self-renew and maintain quiescence may allow 
the development of novel therapeutic strategies that will allow for more efficacious 
and less toxic therapies for these devastating tumors. 
 
 
 
Fig.1.7: Glioma stem cells may represent as novel therapeutic targets: Modified from (Reya et 
2001). Conventional therapies shrink tumors by killing mainly cells with limited proliferative 
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potential, but cancer stem cells may re-establish the tumor. By contrast, therapies targeting cancer 
stem cells render the tumors unable to maintain themselves or grow (CSC- Cancer stem cell).
 
CD133 positive human glioblastoma cells were shown to be resistant to radiation 
therapy, retaining a clonogenic and tumorigenic potential. CD133 positive cells 
increase in number after irradiation of glioblastoma cells in culture and in tumors 
growing in vivo. The CD133 positive cells undergo similar DNA damage to those 
of their CD133 negative counterparts, but they show a better ability to repair strand 
breaks, through a more potent activation of DNA damage checkpoint mechanisms 
(Bao, S. et al, 2006).  
 
1.8. Targeting glioma stem cells via bone morphogenic proteins  
Bone morphogenetic proteins (BMP) belong to the members of the transforming 
growth factor (TGF)-ß family which have important central roles in controlling 
cellular proliferation, differentiation, migration, and survival (Letterio et al, 2000). 
These cytokines constitute a highly conserved set of signaling proteins and can be 
divided into three subgroups: the TGF-ßs, the activins/inhibins, and the bone 
morphogenetic proteins (BMPs), of which the latter constitutes the largest 
subfamily. BMPs are 30–35 kD hetero- or homodimeric proteins originally 
identified by their ability to induce ectopic cartilage and bone formation when 
injected subdermally in rats (Wozney et al 1988). Several studies have 
demonstrated that these proteins play essential roles during embryonic 
development (Wall et al 1994 and, Kingsley et al 1992). For example, BMP2 
knockout mice die in utero, BMP7 knockout mice exhibit neonatal lethality, 
BMP5-deficient mice are viable but exhibit several gross malformations, and 
BMP6 knockout mice are viable and fertile with only moderate malformations 
(Zhang et al 1996, Jena et al 1997, Solloway et al 1998). These phenotypes 
become evident in tissue undergoing morphogenesis, suggesting that BMP 
signaling is particularly relevant when the cells are being directed toward specific 
differentiation pathways.  
So far more than 20 mammalian BMPs have been identified, but only three type I 
and three type II receptors capable of binding BMPs have been cloned in mammals 
(Yamashita et al 1996). BMPs induce the heteromeric complex formation between 
type II and type I receptors. The constitutively active type II kinase activates the 
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type I receptor, which subsequently propagates the signal downstream by 
phosphorylating specific BMP receptor-regulated Smads, i.e., Smad1, Smad5, and 
Smad8 (Yamashita et al 1996, Derynck et al 1997, Miyazono et al 1999). 
Phosphorylated receptor regulated Smads (R-Smads) form heterocomplexes with 
the common partner Smad4 (Co-Smad) and translocate to the nucleus, where they 
participate in the regulation of transcription of target genes (Heldin et al 1997). 
 
 
Fig. 1.8. BMP signalling: The BMPs bind to type I and II receptors and facilitate their association. 
The constitutively active kinase domains of type II receptors phosphorylate type I receptors, and 
this in turn activates the SMAD signaling pathway through phosphorylation of receptor SMADs 
(SMAD1, SMAD5 and SMAD8). These associate with co-SMADs (SMAD4) to form a heteromeric 
complex that translocates to the nucleus and stimulates the expression of a wide range of target 
genes. BMPs can also signal through SMAD-independent pathways, notably via MAP kinases. 
Dorsomorphin inhibits BMP signaling through the SMAD pathway, likely by affecting BMPR-I 
kinase activity. Many of the previously known inhibitors of BMP signaling (such as noggin and 
chordin) act upstream to sequester BMPs and cannot differentiate SMAD-dependent from SMAD-
independent signaling. (Modified from Anderson and Darshan et al 2008).
 
Introduction 18 
 
Neural stem cells express members of the bone morphogenetic protein family and 
their receptors in the adult SVZ  further more they instruct adult neural stem cells 
to adopt a glial fate, (Lledo PM, 2006 et al) BMP antagonist noggin, which is 
released by ependymal cells of brain, induces glial to neuronal fate (Lim D et al, 
2000).  
 
Dorsomorphin which is known as small-molecule inhibitor of BMP signaling 
which has been identified in a screen for compounds that perturb dorsoventral axis 
formation in zebrafish (Anderson and Darshan et al 2008) and found that 
dorsomorphin selectively inhibits the BMP type I receptors and thus blocks BMP-
mediated SMAD1/5/8 phosphorylation and further target gene transcription as 
shown in Fig.1.8.  
 
Promotion of tumor stem-cell differentiation may be an important strategy for 
treatment of brain tumor stem cells. Bone morphogenic proteins (BMPs), which 
normally induce astrocyte differentiation from normal neural precursors, have been 
shown to promote glioblastoma cell differentiation in vitro and in vivo. Most 
importantly, recombinant BMPs induce the suppression of glioblastoma 
tumorigenicity in vivo, possibly though promotion of the differentiation cancer 
stem cells in the tumor (Piccirillo, S.G., et al 2006). 
Recently, our group has discovered that endogenous precursor cells are attracted to 
experimental brain tumors and mediate an anti-tumorigenic effect by inducing 
glioma cell death in the bulk tumor (Glass, R. et al, 2005 and Walzlein, J.H. et al 
2008). However in these initial studies it was not yet shown that the endogenous 
neural precursor cells exert an additional further anti-tumorigenic effect by 
targeting glioma stem cells. In one part of my current work I provide evidence that 
neural precursor cells suppress glioma initiating cells via release of BMP7.  
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2. Molecular mechanisms of glioma growth control 
One major goal of my studies was the characterisation of cell-cell interactions 
between gliomas and the tumor microenvironment. In addition to my work on the 
interaction between glioma, glioma initiating cells and endogenous neural 
precursors (as described above), I worked on a line of research elucidating some 
cell autonomous events in glioma which are important for tumor progression. In 
this part of my thesis I describe a mechanism for ets transcription factor induced 
pro-tumorigenic signalling in glioma. 
 
2.1.   ETS transcription factors and tumors 
In general cancer can be defined as a genetic disease and as a consequence of 
multiple events associated with initiation, promotion and metastatic growth. 
Cancer also results from the loss of control of cellular homeostasis. Cell 
homeostasis is the result of the balance between proliferation and cell death, while 
cellular transformation can be viewed as a loss of relationship between these 
events. Oncogenes and tumor suppressor genes act as modulators of cell 
proliferation, while the balance of apoptotic and anti-apoptotic genes controls cell 
death. All cancer cells acquire similar sets of functional capacities: (1) 
independence from mitogenic/growth signals; (2) loss of sensitivity to “anti-
growth” signals; (3) evade apoptosis; (4) Neo-angiogenic conversion; (5) release 
from senescence; and (6) invasiveness and metastasis (Hanahan D and Weinberg 
RA., 2000). One of the goals of molecular biology is to elucidate the mechanisms 
that contribute to the development and progression of cancer. Such understanding 
of the molecular basis of cancer will provide new possibilities for: (1) earlier 
detection as well as better diagnosis and staging of disease with detection of 
minimal residual disease recurrences and evaluation of response to therapy; (2) 
prevention; and (3) novel treatment strategies and the increased understanding of 
ETS-regulated biological pathways will directly impact these areas.  
Introduction 20 
 
 
 
Fig. 2.1: The theoretical feasibility of ETS-targeted cancer therapy. ETS transcription factors 
are critical for the regulation of expression of several growth factor receptor genes and cell cycle-, 
apoptosis-, angiogenesis-, and invasion and metastasis-related genes. Thus, ETS-targeted cancer 
therapy could be a novel approach to inhibit expression of these cancer-related genes. (Adapted 
from Tsuneyuki Oikawa, Cancer Science, 2004).
As shown in Fig. 2.1. ETS proteins are transcription factors that activate or repress 
the expression of genes that are involved in various biological processes, including 
cellular proliferation, differentiation, development, transformation and apoptosis 
(Oikawa T et al, 20004). Identification of target genes that are regulated by a 
specific transcription factor is one of the most critical areas in understanding the 
molecular mechanisms that control transcription. Furthermore, identification of 
target gene promoters for normal and oncogenic transcription factors provides 
insight into the regulation of genes that are involved in control of normal cell 
growth, and differentiation, as well as provide information critical to understanding 
cancer development.  
As cancer formation and progression is a complex process determined by several 
mechanisms that promote cell growth, invasiveness, neo-angiogenesis, and render 
neoplastic cells resistant to apoptosis. The proto-oncogenic factors ETS are 
important regulators of such mechanisms as it influences various aspects of cell 
behaviour by regulating the transcription of specific genes. 
The Ets transcription factors regulate many genes associated with tumor invasion, 
angiogenesis, cell adhesion, and organs development (Dittmer et al, 1998). Ets 
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family of transcription factors comprising more than 30 different members sharing 
a highly conserved DNA binding motif termed the ETS domain and through this 
domain they bind to specific purine-rich DNA sequence containing a conserved 
motif of GGAA/T in the middle of ten base pairs of DNA and depending on which 
Ets transcription proteins are binding these flanking sequences are variable 
(Wasylyk et al, 1993). 
These flanking sequences are variable and there is evidence that they help to 
determine which Ets proteins will bind (reviewed in Wasylyk et al., 1993; 
Wasylyk and Nordheim, 1997; Watson and Seth, 2000). Ets-1 is the founding 
member of the Ets family and was initially identified as the protooncogene 
corresponding to the v-Ets oncogene of the E26 leukemia virus. In humans, Ets-1 
is expressed at high levels in proliferating vascular endothelial cells of the embryo 
and in blood vessels of the adult during angiogenesis (Wernert et al., 1992). In the 
hematopoietic system the analysis of targeted mutants has revealed an essential 
role for Ets-1 in the differentiation of all lymphoid cells; it was found to be 
essential for the development of functional NK cells (Barton et al., 1998) and for 
survival and maturation of B and T cell lineages (Bories et al., 1995; Muthusamy 
et al., 1995).  
 
 
 
Fig. 2.1.1. ETS transcription factor involvement in cancer. (adapted from European Journal 
of Cancer, 2005). 
The protumorigenic effects of ets transcription factors are long known (Dittmer and Nordheim, 
1998) and especially the invasion promoting role of the founding member of the ets family ets1 has 
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been described in glioma (Kita et al., 2001; Kitange et al., 1999a; Kitange et al., 1999b). The major 
mechanism underlying oncogenic activities of ets-1 involves transcriptional activation of 
invasive/proliferative related genes by ets-1 binding to DNA. However, it remained largely 
unexplored how ets factors promote glioma proliferation (Kitange et al., 1999a). 
 
2.2. Transferrin receptor (TfR) 
In this part of my project I investigated the role of ets-transcription factor induced 
transferrin receptor (TfR) overexpression. TfR overexpression in gliomas is well 
known (Recht et al., 1990), but as yet largely unexplored field of research. I 
provide evidence that ets-induced TfR expression causes aberrant intracellular iron 
accumulation, which catalyses the formation of reactive oxygen species (ROS) and 
subsequently leads to accelerated tumor growth and cytotoxicity. Hence I give here 
a short introduction to TfR mediated iron accumulation and Iron mediated ROS 
generation. 
Iron (Fe) is an essential requirement for the activity of many metabolic processes. 
This is because Fe-containing proteins catalyze key reactions involving energy 
metabolism and DNA synthesis. In fact, without Fe cells are unable to proceed 
from the G1 to the S phase of the cell cycle. In addition, Fe appears to play a 
critical role in the expression and regulation of a number of molecules that control 
cell cycle progression e.g. p53, GADD45 and WAF1/p21 (Darnell G et al 1999 
and Gao J et al 1999). Cells take up iron by the receptor mediated uptake of 
transferrin bound iron via its binding to the transferrin receptor (TfR) which is 
internalised by receptor mediated endocytosis as illustrated in Fig. 2.2. The 
transferrin receptor is a transmembrane glycoprotein consisting of two 90 kDa 
subunits and Transferrin (Tf) is ligand for the TfR, which is a member of the 
family of Fe-binding glycoproteins (Morgan, E. H. et al, 1996).  
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Fig. 2.2: Schematic representation of the TfR internalisation upon binding of Tf to its 
receptor. Plasma Tf-Fe binds to transferrin receptor on cell surface transferrin receptor with Tf-Fe 
endocytosed into cell iron regulatory proteins that regulate cellular iron balance by controlling 
synthesis of apoferritin versus Tf receptor. Iron not required binds to apoferritin to be stored as 
ferritin in cell. 
 
2.3. Transferrin receptor and its expression in brain 
The expression level of the TfR depends on the level of iron supply and rate of cell 
proliferation. The iron concentration determines TfR synthesis and expression via 
an iron-responsive element (IRE) in the mRNA of the TfR (Kuhn, L. C. et al, 
1991, Casey, J. L. et al, 1989). This IRE is also found in the mRNA of ferritin, a 
protein that can store iron (Kuhn, L. C. et al, 1991). In cases of low iron 
concentrations, a so called IRE binding protein stabilises the mRNA of the TfR, 
which can therefore be translated. The mRNA of ferritin is in low-iron situations 
less stable and is therefore translated to a lesser extent. Recently, a second TfR 
(TfR-2) has been identified (Trinder, D. and Baker, E. et al, 2003), which does not 
contain an IRE in its mRNA. TfR-2 is differentially distributed from TfR and has a 
25-fold lower affinity for Tf.  
The TfR is expressed mainly on hepatocytes, erythrocytes, intestinal cells, 
monocytes, as well as on endothelial cells of the BBB, transferrin/iron is likely to 
reach the brain through an endocytotic process at the endothelial cells (Morgan, E. 
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H. et al, 1996, Ponka, P. and Lok, C. N. et al, 1999). Furthermore, in the brain the 
TfR is expressed on choroid plexus epithelial cells and neurons (Moos, T. and 
Morgan, E. H. et al, 2000) and also oligodendrocytes are believed to be the 
predominant iron-containing cells in the brain and have a special requirement of 
iron for myelin production, and immature oligodendrocytes express TfR for iron 
acquisition (Connor, J.R., Menzies, S.L.et al, 1996). In normal brain, TfR 
immunostaining is detected primarily in endothelial and glial cells, whereas 
neoplastic cells from nearly all brain tumors are found to be TfR-positive (Recht, 
L., C.O.et al, 1990, Prior, R. et al, 1990) this is mainly due to the high iron 
requirements for malignant growth (Ponka, P. and Lok, C. N. et al, 1999). 
 
2.4. Transferrin receptors and tumor cells  
Most malignant and proliferating cells express high numbers of TfRs as compared 
to their normal and quiescent counterparts and the first direct evidence of the 
proliferation-associated expression of TfR was demonstrated in several 
lymphoblastoid cell lines and activated peripheral blood lymphocytes which have 
high numbers of transferrin binding sites (Larrick, J.W. et al, 1979). Subsequently, 
numerous reports (Kuhn, L.C. et al, 1990, Neckers, L.M. et al, 1991) confirmed 
that  virtually all cell lines and normal proliferating cells possess high numbers of 
TfRs, TfR expression increases upon mitogenic stimulation and diminishes upon 
terminal differentiation and growth arrest and furthermore anti-TfR antibodies that 
can block transferrin binding and hence iron uptake inhibit cell proliferation 
(Trowbridge, I.S. et al, 1982).  In some tumors like in breast cancers TfR has been 
discussed to have growth factor like functions (Cavanaugh et al 1999) which will 
support the notion that the TfR is a proliferation-associated marker. The 
explanation for the proliferation-associated expression of TfR is attributed in part 
to an increased requirement of iron for synthesis and functioning of numerous iron-
containing proteins, in particular ribonucleotide reductase, which is a rate-limiting 
enzyme in DNA synthesis (Chitambar, C.R. et al, 1995). Gliomas are long known 
to over-express TfR and the extent of TfR expression positively correlates with 
tumor grading (Recht L et al 1990) but the exact role of TfR over expression in 
glioma is largely unexplored. 
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2.5. Transcriptional regulation of TfR 
Kuhn and coworkers reported the first genomic clone for the transferrin receptor 
by expression and cloning techniques (Kuhn, L.C. et al, 1984). The human TfR 
gene was found to contain at least 19 exons distributed over 31 kb of DNA and 
contains a translated region of 2,280 nucleotides in their respective cDNA clones.  
TfR gene transcription is activated during cell proliferation (Seiser, C. et al, 1993), 
cell transformation (Beard, P. et al, 1991) and differentiation of immature 
erythroid cells to hemoglobin synthesizing cells (Chan, R.Y.Y. et al, 1994, Chan, 
L.N. et al, 1992). On the other hand, gene transcription is comparatively inactive in 
the quiescent state of the cells, that is during growth arrest and terminal 
differentiation in the nonerythroid cells (Lok, C.N. et al, 1996). TfR gene 
transcription is believed to be controlled by cellular signals involved in the cell 
growth and differentiation, resulting in the expression of TfR for iron demand 
during cell proliferation or heme synthesis. The TfR gene promoter region (fig. 
1.10) is GC-rich and contains a TATA box about 30 bp upstream from the known 
transcriptional start site. A consensus SP-1/GC-rich sequence is located near the 
TATA box and a sequence as short as 47 bp upstream of the transcriptional start 
site has been found to be sufficient for driving the basal transcription of the 
reporter gene as shown by reporter gene assays (Owen, D. et al, 1987).      
 
 
Fig. 2.5. TfR gene promoter region. Part of the TfR promoter region that is critical for its 
expression. The underlined sequences represent elements similar to certain consensus cisacting 
elements. Sequence similarity to consensus regulatory cis-elements and putative binding factors are 
indicated (see text for explanation). Bold typeface identifies bases identical to the TfR gene 
elements (Sieweke, M.H. et al, 1996, Ouyang, Q. et al, 1993, Roberts, M.R. et al, 1994). CRE = 
cAMP-responsive element; CREB = CREbinding protein; PSE = proximal sequence element. 
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One of the most important transcriptional control mechanisms of the TfR is the 
upregulation of the receptor expression in developing erythroid cells. In an avian 
erythroblastic cell line, the transcription factor Ets-1 could stimulate the erythroid 
differentiation and was also found to enhance the TfR promoter activity by 2- to 3-
fold via an Ets binding site close to the TRE-like sequence (Sieweke, M.H. et al, 
1996). Interestingly, overexpression of Maf B, a direct repressor of Ets-1, 
downregulated the TfR expression and inhibited the erythroid differentiation, 
without affecting cell growth (Sieweke, M.H. et al, 1996). Therefore, an erythroid-
specific transcriptional control of the TfR seems to operate. In tumors like in 
gliomas it is unclear which transcription factors regulate TfR transcription.  
 
2.6.  TfR over expression and reactive oxygen species generation 
Reactive oxygen species (ROS) have been shown to be associated with a wide 
variety of pathological phenomena such as carcinogenesis, inflammation, radiation 
and reperfusion injury. Iron, the most abundant transition metalion in our body, 
may work as a catalyst for the generation of ROS in pathological conditions. The 
major reactive oxygen species (ROS) include oxygen radicals such as superoxide 
(O2−) and hydroxyl ( OH), as well as non-radical derivatives of molecular oxygen 
(O2), such as hydrogen peroxide (H2O2). Whereas O2− and H2O2 do not exhibit 
strong reactivity with other bio-molecules, their reaction generates the highly 
reactive OH radical, which probably accounts for most of the oxidative damage 
attributed to ROS (Halliwell & Gutteridge, 1999).  
In healthy living cells, one or more of redox regulatory mechanisms are activated 
in response to a transient increase in intracellular ROS to prevent oxidative stress. 
A disturbance in the tight balance between ROS production and elimination, either 
via augmentation of ROS generation or defective/deficient anti-oxidant defenses 
for their elimination, results in a build up of intracellular ROS and may lead to 
persistent changes in signal transduction and gene expression (Sauer et al., 2001), 
thereby giving rise to oxidative stress-related pathological states (Burdon, 1995 
and Burdon, 1996). In case of tumors like in glioma over expression of transferrin 
receptors may lead to excessive iron intake into the tumor cells and it is unclear 
about the fate of free iron in these tumor cells, as from previous reports that free 
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iron catalyse Fenton reaction  and generates reactive oxygen species as shown in 
the below reaction. 
Fe2+ + H2O2 → Fe3+ + OH· + OH−
 Fe3+ + H2O2 → Fe2+ + OOH· + H+
Fenton Reaction: Ferrous Iron(II) is oxidized by hydrogen peroxide to ferric 
iron(III), a hydroxyl radical and a hydroxyl anion. Iron (III) is then reduced back to 
iron(II), a peroxide radical and a proton by the same hydrogen peroxide 
(Halliwell.,1993).
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3. Aim of the study 
In a first project of my thesis I aim at elucidating the molecular mechanisms of the 
anti-tumorigenic effect of endogenous neural precursor cells against glioma. 
1. To investigate if neural precursors express (anti-tumorigenic) bone morphogenic 
proteins (BMP) in vitro and in vivo. 
2. To find out if neural precursors attracted towards gliomas maintain BMP 
expression and if NPCs may (constitutively) release these BMPs. 
3. To study if glioma initiating cells may receive BMP signals, and to investigate if 
BMP signalling has an impact on the tumorigenicity of glioma intitiating cells. 
 
In a second project of my thesis simultaneously I aim to charactirise a cell 
autonomous protumorigenic effect in glioma mediated by the ets transcription 
factors. 
 
1. To describe the significance of enhanced transferrin receptor-expression for 
glioma proliferation 
2. To investigate the role of Ets in transcriptional regulation of transferrin 
receptors and in glioma progression 
3. To explore the connection between increased redox signalling and 
augmented  transferrin receptor expression in glioma 
4. To identify the potential targets of redox signalling which mediate 
accelerated  glioma proliferation 
5. To identify the potential targets of redox signalling, which mediate to 
accelerated glioma expansion and infiltration. 
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4. Materials and Methods  
4.1. Materials  
4.1.1. Devices 
CCD camera  Proscan, Germany 
Centrifuges Eppendorf, Germany 
Clean bench Biowizard, USA 
Neubauer counting chamber LaborOptik, Germany 
Cryosystem FCS  Leica Microsystems, Germany 
Enterprise laser  Coherent, USA 
FACSVantage SE flow cytometer  Becton Dickinson, USA 
Fluorescence microscope Axioplan  Zeiss 
G-Box gel documentation system Syngene, UK 
Gelelectrophoresis device BioRad, Germany 
Gradient cycler Eppendorf 
Incubator Labotect, Germany 
Inverted fluorescence microscope Axiovert 
100 
Zeiss 
Micro-infusion pump World Precision Instruments, 
Germany 
Microscopes Zeiss 
Nucleofector Amaxa, Germany 
Photometer Eppendorf 
Power Pack 300 BioRad 
Scales Sartorius, Germany 
Spectral confocal microscope TCS SP2 Leica, Germany 
Speed Vac Bachofer, Germany 
Stereotactic head holder David Kopf Instruments, USA 
Thermocycler T3000 Biometra, Germany 
Trans blot SD BioRad 
Victor 1420 Multilabel Counter Perkin Wallac GmbH, Germany 
Vortex Janke & Kunkel, Germany 
Water bath GFL, Germany 
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4.1.2. Plastic ware and other material 
96-well plates (for DELFIA TUNEL assay) PerkinElmer, Germany 
96-/ 24-/ 6-well plates TPP, Switzerland 
Cuvettes Eppendorf 
Falcon cell culture inserts (0.4 µm) for 6-
well 
Becton Dickinson 
Falcon tubes (15 ml, 30 ml) TPP 
Hyperfilm ECL Amersham Biosciences, USA 
Parafilm Pechiney Plastic Packaging, USA 
Saran wrap Dow Chemical Co, USA 
Tissue culture dishes (60 mm, 30 mm) TPP 
Tissue culture flasks (25 cm2, 75 cm2) TPP 
4.1.3. Chemicals 
Acrylamide/Bisacrylamide 30 % solution Sigma, Germany 
Agarose Roth, Germany 
Ampicillin Roche, Germany 
APS (ammoniumpersulfate) Merck, Germany 
Aqua Poly/Mount Polysciences, Inc, USA 
BrdU (5-bromo-2-deoxyuridine) 
labelling reagent  
Sigma, Germany  
CHAPS (3-[(3-Cholamidopropyl) 
dimethylammonio]-1-propanesulfonate) 
Amersham Biosciences, Germany 
Complete proteinase inhibitor  Roche, Germany 
DAPI (4’,6-Diamidino-2-Phenylindol-2HCl) Sigma 
DCFH-DA (2’7’dichlorodihydrofluorescin 
diacetate) 
Molecular probes, Germany 
DNAse (desoxyribonuclease) Worthington, USA 
dNTPs (desoxyribonucleosidtriphosphate) Invitrogen, USA 
Dorsomorphin (Compund-C)  
dTTP (2’-deoxythymidine 5’-triphosphate) Roche 
ECL Plus (Western Blotting Detection 
Reagent) 
Amersham Biosciences 
Ethanol Roth 
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FCS (fetal calf serum) Gibco 
G418 (= neomycin) Gibco 
Gel blotting paper Roth 
Glucose Roth 
Glycerol Sigma 
Hybond-P PVDF membrane Amersham Biosciences 
Isopropanol Roth      
Laminin Invitrogen 
L-Glutamine Biochrom AG 
Lipofectamine 2000 transfection reagent Invitrogen 
Matrigel Becton Dickinson 
Methanol Roth 
MgCl2 Invitrogen 
PBS (phosphate buffered saline) Gibco 
Penicillin/Streptomycin Biochrom AG, Germany 
PFA (paraformaldehyde) Merck 
Poly-L-Ornithine Sigma 
Polyvinylalcohol  Sigma 
Rainbow molecular weight marker Amersham Biosciences 
Sucrose Merck 
TdT (Terminal deoxynucleotidyl Transferase) 
–buffer 
Amersham Biosciences 
TEMED (N,N,N’,N’ Tetramethyl-Ethylen-
Diamine) 
Amresco, USA 
Tris Roth 
Triton X-100 Merck 
Trypsin/EDTA (Ethylenediaminetetraacetic 
acid) 
Biochrom AG 
4.1.4. Enzymes 
SuperScript II Reverse Transcriptase  
(200 U/µl) 
Invitrogen 
Taq-Polymerase Invitrogen 
TdT-enzyme (500 U) Amersham Biosciences 
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4.1.5. Kits 
BCA Protein Assay Kit Pierce, USA 
BMP7 ELISA kit R&D systems, USA 
BrdU Cell Proliferation Assay Calbiochem, Germany  
ChIP-IT™ Express            Active Motif, Belgium 
Cell line and Stem cell Nucleofector Kit Amaxa, Germany 
Endo Free Plasmid Maxi Kit Qiagen, Germany 
Dual-Luciferase assay kit Promega, Germany 
QIAprep® Spin Miniprep Kit Qiagen, Germany 
Rneasy Mini Kit Qiagen, Germany 
Site directed mutagenesis kit Stratagene, Germany 
4.1.6. Antibodies 
4.1.6.1.Primary antibodies 
Tab. 4.1. Overview of applied primary antibodies 
Antigen Host Dilution Supplier 
5-Bromodeoxyuridine (BrdU) Rat 1:500 Biozol, 
Germany 
BMP7 Mouse 1:1000 Cell signaling 
technology, 
USA 
CD133 Mouse 1:200 Milteny 
Biotec 
Transferrin receptor Mouse 1:400 Dianova, 
Germany 
Ets1 (C-20) Human 1:500 Santa Cruz 
Biotechtechno
logy, USA 
Ets-1 Rabbit 1:400 Cell Signaling 
technology, 
USA 
Glial acidic fibrillary protein (GFAP) Rabbit 1:500 Dako 
Cytomation, 
Denmark 
Green fluorescent protein (GFP) Goat 1:1000 Acris 
Antibodies, 
Germany 
MAP2 Mouse 1:1000 Sigma-
Aldrich, 
Deisenhofen, 
Germany 
P21 Rabbit 1:100 Santa Cruz 
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Biotechtechno
logy, USA 
Psmad1-5-8 Rabbit 1:400 Cell signaling 
technology, 
USA 
PSA-NCAM Mouse 1:400 Chemicon, 
USA 
Prominin(CD133) Mouse 1:10 Milteny 
biotech, 
Germany 
Ki67  Rabbit  1:400 Novocastra 
Laboratories 
Ltd., UK 
Smad 1-5-8 Rabbit 1:1000 Santa Cruz 
Biotechtechno
logy, USA 
 
 
4.1.6.2.Secondary antibodies 
Tab. 4.2. Overview of applied secondary antibodies 
Antigen Host Conjugation Dilution Supplier 
Mouse IgM Donkey Rhodamine 
Red 
1:125 Jackson ImmunoResearch 
Laboratories, USA 
Goat IgG Donkey Rhodamine 
Red 
1:125 Jackson ImmunoResearch 
Laboratories 
Rabbit IgG Donkey FITC 1:125 Jackson ImmunoResearch 
Laboratories 
Rat IgG Donkey Biotin 1:125 Jackson ImmunoResearch 
Laboratories 
 
 
Substrate Conjugation Dilution Supplier 
Streptavidin HRP 1:10,00
0 
Amersham Biosciences 
Streptavidin Cy5 1:200 Jackson ImmunoResearch 
Laboratories 
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4.1.7. Oligonucleotides (PCR primers) 
Tab. 4.3. Overview of used oligonucleotides 
Name Sequence (5’Æ 3’) Application Source 
m-EBS 
 (forward) 
CTCGCGAGCGTACGTGCCTCA
CATCGTGACGCACAGCCCCC
CTGG  
PCR MWG 
m-EBS 
 (reverse) 
CCAGGGGGGCTGTGCGTCAC
GATGTGAGGCACGTACGCTC
GCGAG  
PCR MWG 
mutated-
AP1/Cre/EBS 
(forward) 
CGTGCCTCACATCGTGTGGTG
CAGCCCCCCTG  
PCR MWG 
mutated-
AP1/Cre/EBS 
(reverse) 
CAGGGGGGCTGCACCACACG
ATGTGAGCGACG  
PCR MWG 
mutated 
AP1/Cre 
 (forward) 
CGTGCCTCAGGAAGTGTGGT
GCAGCCCCCCTG  
PCR MWG 
mutated 
AP1/Cre 
 (reverse) 
CAGGGGGGCTGCACCACACT
TCCTGAGGCACG 
PCR MWG 
hAlk-2 
(forward)    
ACT ACA GCC TGG AGC ATT 
GGT AAG 
PCR MWG 
hAlk-2 
(reverse) 
ATC TGC CCA CAG TCC TTC 
AAG C 
PCR MWG 
hAlk-6 
(forward) 
CGT CCA AAG GTC TTG CGT 
TG 
PCR MWG 
hAlk-6 
(reverse) 
CCC GAC ACT GAA AAT CTG 
AGC C 
PCR MWG 
hBMPRII 
(forward) 
ACC ATG AAT GGT GTG GCA 
GGT AGA 
PCR MWG 
hBMPRII 
(reverse) 
CTT CAT CAT GGC CAG CTT 
GTT GCT
 
PCR MWG 
ß-actin 
(forward) 
CCC TGA AGT ACC CCA TTG 
AA 
PCR MWG 
ß-actin 
(reverse) 
GTG GAC AGT GAG GCC AAG 
AT 
PCR MWG 
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4.1.8. Plasmids 
Tab. 4.4. Overview of plasmids 
Name Source Properties 
EtsDN construct H, Sato  Japan Dominant negative form 
expression of ets 
pTRE-tight M Gossen, MDC, 
Berlin, Germany 
Tetracycline responsive 
plasmid 
pCEP4-IRES-EGFP Invitrogen Expresses Enhanced green 
fluorescent protein 
pRc-CMV +TfR pRc-CMV from 
invitrogen 
Transferrin receptor over 
expressing construct  
pCD-TR1 Kuhn ORF of TfR 
 
4.1.9. Media and buffer 
4.1.9.1.Cell culture media 
FCS was inactivated in the water bath for 30 min at 60°C prior to use. All media 
were purchased from Gibco, USA. 
Tab. 4.5. Overview of media and buffer in cell culture 
Cell culture medium for GL261 and 
U373: 
DMEM/10 % FCS/1 % PGS 
10 % FCS 
100 U/ml penicillin 
100 µg/ml streptomycin 
0.2 mM L-glutamine 
in DMEM 
Cell culture medium for electroporation 
of U373 
10 % FCS 
0.2 mM L-glutamine 
in RPMI 
Cell culture medium for NPCs and for 
glioma stem cells(GSCs): 
NB/B27 
20 % B27 
100 U/ml penicillin 
100 µg/ml streptomycin 
10 % L-glutamate 
3 mg/ml glucose 
20 ng/ml FGF 
20 ng/ml EGF 
in Neurobasal A 
Freezing medium for NPCs and GSCs 10 % DMSO 
in NB/B27 
PPD solution 2.5 U/ml papain 
250 U/ml DNAse 
1 U/ml dispase II (neutral protease) 
in DMEM 4.5 g/l glucose 
Fixans 4 % formaldehyde 
0.5 % glutaraldehyde  
in 0.1 M phosphate buffer 
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4.1.9.2.Bacteria propagation 
Tab.4.6. Medium for bacterial cultures 
Luria-Bertani medium (LB) 10 g Bacto-tryptone 
5 g Bacto-Yeast extract 
5 g NaCl 
adjust pH to 7.5 with NaOH, autoclave, 
cool to 55°C and add antibiotics 
suitable for the expression plasmid 
 
4.1.9.3. Buffers for immunolabelling  
Tab. 4.7. Buffers for immunolabelling  
TBS 100 mM Tris 
150 mM NaCl, pH 7.4 
TBS+ % Triton X-100  
3 % donkey serum 
in TBS 
4.1.9.4. Buffers for PCR 
Tab. 4.8. Buffers for PCR 
10 x loading buffer  1.7 % xylen cyanol 
1.7 % bromphenolblue 
80 % saccharose 
in H2O 
50 x TAE (Tris-Acetate-EDTA) buffer 242 g Tris-Base 
57.1 ml acetic acid 
0.5 M EDTA 
ad 1 l H2O, pH 8.0 
 
4.1.9.5.Buffers and solutions for Western Blots 
Tab. 4.9. Buffers and solutions for Western Blots 
Sample buffer 1 % SDS 
1 % Triton X-100 
Complete proteinase inhibitor  
in TBS, pH 7.4 
10 % APS 100 mg NH4 persulfate  
in 1 ml H2O bidest. 
Lower gel buffer  72.7 g Tris 
1.6 g SDS 
ad 400 ml H2O bidest., pH 8.8 
Upper gel buffer 18.2 g Tris 
1.2 g SDS 
ad 300 ml H2O bidest., pH 6.8 
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10 x Running buffer 30 g Tris 
140 g glycine 
10 g SDS 
ad 1 l H2O bidest. 
Transfer buffer 2.93 g glycine 
5.81 g Tris 
0.375 g SDS 
ad 800 ml H2O and 200 ml methanol 
Washing buffer 0.5 % Tween-20 
in TBS 
Blocking buffer 3 % fat free milk powder  
in washing buffer 
4.1.10. Software 
Tab. 4.10. Software 
Product name Supplier 
Adobe Photoshop CS Adobe Systems Inc. USA 
analySIS 3.2  Soft Imaging System, Germany 
Leica Confocal Software Leica, USA 
Microsoft Office Microsoft, USA 
Image Pro Media Cybernetics, Silver Spring, MD, USA 
Volocity 2.6.1. Volocity, USA 
 
4.2. Methods  
4.2.1. In vivo inoculation of glioma or glioma stem cells into the mouse  
4.2.1.1.Animals and Anaesthesia 
All animals were sacrificed according to the permit (LaGeSo, 0122/07) given by 
the Office for Health Protection and Technical Safety of the regional government 
of Berlin and obeyed the rules laid down in the European Community Council 
Directive. 
Wild type C57BL/6 (Charles River Breeding Laboratories; Schöneiche, Germany) 
and Nude mice (genetic background athymic Nude-Foxn1, Harlan, Holland) were 
housed with a 12h light/dark cycle and received food and libitum. All 
governmental and institutional regulations regarding animal ethics were followed. 
Mice were anaesthetised with intraperitonal injections of a 0.1 % xylazyne and 1.5 
% ketamine hydrochloride mixture in 0.9 % NaCl. 10 µl of the anaesthetic mixture 
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was injected per 1 g of mouse body weight. The eyes of the mice were carefully 
covered with glycerin fat to avoid cornea drying.  
4.2.1.2.Glioma cell or GSCs inoculation into the mouse brain  
Anaesthetised C57/BL6 mice were immobilized and mounted onto a stereotactic 
head holder in the flat-skull position. The skin of the skull was dissected with a 
scalpel blade and the skull surface was disinfected with a 10 % potassium iodide 
solution. The skull was carefully drilled with a 20 G needle tip at 1 mm anterior 
and 1.5 mm lateral to the bregma. Then a 1 µl syringe with a blunt tip was inserted 
to a depth of 4 mm and retracted to a depth of 3 mm from the dural surface. 1 µl of 
the glioma cell suspension (2 x 104 cells/µl) was slowly injected over 2 min into 
the pre-cast hole and in case of glioma stem cells only 100/µl were taken to inject 
into mice. The needle was then slowly taken out from the injection canal and the 
skin was sutured with a surgical sewing cone. 
4.2.1.3.BrdU injections 
For BrdU labelling experiments, animals received intraperitonal injections of 50 
mg of BrdU/kg of body weight at a concentration of 10 mg/ml BrdU in sterile 0.9 
% NaCl solution twice daily for three days until 24 h before the glioma cell 
injection.  
4.2.2. Survival study 
Glioma stem cells were pre-treated with rBMP7 or NPC-conditioned medium for 
5days or left untreated control cells were injected into Nude mice of P25. The 
application of the cells was performed as described as above. Only 100cells/ µl of 
glioma stem cells were taken for inoculation into mouse. 
4.2.3. Tumor size measurement 
Tumor xenografts were obtained by subcutaneous (s.c) injection of one million 
cells of U373wt, U373EtsDn, TfR /U373 Ets Dn into the right and left flanks of 
female nude mice and two more groups which were injected with U373wt were 
given DFO and NAC in drinking water.  
The tumors were measured in two diameters and the tumor volume (TV) was 
calculated by the formula TV: length (mm) x width2 (mm)/2= mm3 (Geran RI et al, 
1977) over the time course of 2 months. 
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4.2.4. Paraformaldehyde fixation 
The mice were killed by a 10 % ketamin intraperitonal injection and perfused with 
an intracardiac injection of freshly prepared 4 % paraformaldehyde (PFA) solution 
(30 ml per animal). The PFA perfusate was replaced by a 0.9 % NaCl solution. 
After that, the skull was opened and the brain was carefully removed and postfixed 
overnight in 4 % PFA. Finally, the brains were cryopreserved in 30 % sucrose.  
 
4.2.5. Immunohistochemistry of brain sections (floating sections) 
The PFA perfused cryoprotected brains were rapidly frozen in dry ice and mounted 
onto a sliding microtome. 40 µm thick sections were collected into a CPC 
(25 % glycerol and 25 % ethylenglycol in 0.05 M phosphate buffer). Before 
immunolabelling, the sections were washed three times with TBS and 
subsequently blocked by incubating them in 3 % H2O2 (in 50 % methanol) for 30 
min at room temperature on a shaker. The sections were again washed three times 
with TBS and incubated in TBS+ for 30 min for permeabilisation. Then, the 
sections were incubated for 48 - 72 h at 4°C with relevant primary antibodies. 
Sections were washed three times with TBS and incubated with the fluorescence 
conjugated secondary antibodies (1:125) for 3 h at room temperature. After a final 
wash they were mounted onto microscope glass slides, covered with coverslips and 
stored at 4°C until used for microscopical analysis. 
4.2.6. Cell lines and plasmid constructs 
The cDNA-encoding Ets-DN (Kind gift from H. Sato), which lacks a transcription 
activation domain and corresponds to amino acid residues 306–441 (Kita D et al, 
2001), was inserted into the pCEP4-IRES-EGFP expression plasmid, allowing 
bicistronic expression of EtsDN and EGFP. Bulk U373 EtsDn cultures were 
obtained by stable transfection of that construct into U373 cells with 
Lipofectamine 2000, Carl. Transfected U373 cells were cultured in the presence of 
800µg/ml hygromycin B, and resistant cells were cloned. U373 wild type cells 
were seeded at clonal density and then cultivated to give rise to a number of clonal 
U373-WT cultures. A tetracycline inducible system was used to get single clones 
of etsDn expressing cells of U373. EtsDn-IRES-EGFPwas subcloned in to the 
pTRE-tight vector (kind gift from M. Gossen). Doxycycline (200ng/ml) was used 
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to induce the expession of the insert. U373-etsDN cultures were then grown from 
single clones of the stably transfected cells (as described for U373-WT cells). 
Further, I subcloned the ORF for TfR (from pCD-TR1; a kind gift from from L. 
Kuhn) into a CMV promoter containing vector (Rc-CMV) and then transfected 
U373 cells constitutively expressing EstDN and WT 1321N1 cells with the TfR 
construct by using Lipofectamin-2000 Selection of cells stably expressing 
etsDN+TfR was achieved with hygromycin and  G418 (0.6mg/ml). Finally, 
cultures were grown from single clones of U373-etsDN+TfR cells. All reagents 
were purchased from Sigma, unless otherwise specified. 
4.2.7. Cell culture of glioma cells 
The Human glioma U373 and mouse cell line GL261cell line were purchased from 
the National Cancer Institute, NCI-Frederick (MD, USA). Both U373 and GL261 
glioma cells were grown in DMEM/10 % FCS/1 % PGS in T-25/T-75 tissue 
culture flasks. The mouse GL261 cell line was selected for its isogenity to the 
mouse strain C57/BL6, which was used for the animal experiments. The medium 
was changed every two days and cells were passaged when the cell density in the 
flask reached confluency. Cell cultures were maintained in the incubator at 37°C in 
a humidified and by 5 % CO2 conditioned atmosphere. 
4.2.8. Cell culture of neural precursor cells  
Mice were decapitated and skin and skull were removed. The brain was dissected 
from the brain stem and transferred into cold PBS/Glucose (4.5 g/l). The 
cerebellum and olfactory bulb were taken off and cross sections of the brain 
containing the subventricular zone (SVZ) were made.  
The lateral ventricles of the SVZ were microdissected, collected in a  
15 ml tube and centrifuged (500 g, 5 min, 4°C). The collected tissue was incubated 
with occasional mixing in PPD solution (5 ml/animal) for 40 min at 37°C. The 
tissue was washed three times with PBS to remove the PPD. Cells were plated in 
10 cm dishes in NB/B27 (two to three animals per dish). Cultures were incubated 
at 37°C, 5 % CO2 and medium was changed on the next day. The cells were 
cultured until they formed semi-adherent neurospheres. For splitting, NPCs were 
collected by centrifugation (500 g, 5 min, 4°C) and dissociated by pipette-mixing 
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for 35 times. The cells were counted and seeded in a clonal density of 500,000 per 
10 cm dish in NB/B27.  
For adherent cultivation, cells were put on dishes coated with poly-L-ornithine and 
laminin. These dishes were coated by first incubating them with poly-L-ornithine 
solution (10µg/ml in H2O) overnight at room temperature. On the next day they 
were rinsed twice with sterile H2O and incubated with a laminin solution (5µg/ml 
in PBS) overnight at 37°C. 
 
4.2.9. Isolation and Cell culture of Glioma stem cells 
Mouse glioma stem cells (Gl261): Bulk cultures of Gl261 cells were grown in NB-
27 medium (NPC culturing medium) for at least 4-6 weeks and stem cell like cells 
were isolated by using Cd133 antibody labeling from FACSorter which were 
around 0.7-1% and were further enriched to around 90% glioma stem cells. 
Human glioma stem cells: NCH421k, these cells were obtained from patients 
suffering Glioblastoma multiforme and were enriched further to more than 90% 
CD133 positivity, where as B4 cells are 35% positive for CD133. Both human and 
glioma stem cells are grown in NB/B27 medium which is the medium I generally 
culture also neural precursor cells. 
4.2.10. Hippocampal cell culture and immunocytochemistry 
Hippocampal cultures from E19 Wistar rats were prepared as previously described 
(Meier J and Grantyn R, 2004) and maintained in B27- and 1% FCS-supplemented 
Neurobasal medium. The initial cell density was 45,000/cm2. Tumor cells 
(2,800/cm2) were added to the hippocampal cell culture 2 weeks after plating. 
After 24 hours of tumor cell growth hippocampal neurons were processed for 
immunocytochemistry. Dendrites were labeled with a mouse monoclonal antibody 
directed against microtubule-associated proteins (MAP) 2a and 2b and a cyanine 
(Cy3)-coupled goat-anti mouse antibody. Degenerating neurons were then 
identified according to the appearance of an abnormal dendrite morphology 
(length, dendritic swellings and varicosities, fragmentation, as described (Ferrer I, 
1999). In addition, the total number of MAP2-positive neurons per viewfield was 
quantified. Data are presented as means ± s.e.m. obtained from three independent 
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experiments, each including analysis of at least 2 different cover slips and 5-10 
randomly chosen view fields.  
4.2.11. Hematoxylin and Eosin staining 
The glioma-cell-implanted mice along with control mice brains were postfixed 
after the perfusion fixation with 4% paraformaldehyde, and cut with a vibratome 
into 40 mm coral sections. For H & E staining, brain sections were mounted on 
slide and stained with Harris hematoxylin for 2 min first, and then counterstained 
with alcoholic eosin. 
4.2.12. BrdU proliferation assay 
Glioma cells (5 x 103/well) were seeded on a poly-L-ornithine-/laminin-coated 96-
well plate. The next day, the medium was removed and replaced by fresh medium. 
Cells were incubated for three days. BrdU label was added to the cells 18 h prior to 
fixation. The next day, cells were fixed with 200 µl fixative/denaturing solution for 
30 min. After that, 100 µl of the anti-BrdU antibody (1:100 in antibody dilution 
buffer) was added to the cells for one hour at room temperature. Cells were washed 
three times with 1 x wash buffer and 100 µl of peroxidase goat anti-mouse IgG 
HRP conjugate was added for 30 min at room temperature. Cells were again 
washed three times with wash buffer and the plate was entirely flooded with dH2O. 
After complete H2O removal, cells were incubated with 100 µl substrate solution 
for 15 min at room temperature in the dark. The reaction was stopped with 100 µl 
of stop solution. The absorbance was measured using a spectrophotometric plate 
reader at dual wavelengths of 450 – 540 nm.  
4.2.13. Immunolabelling  
Cells on cover slips were fixed with 4 % PFA for 10 min and then washed three 
times with PBS. To permeabilise the cell membrane, cells were incubated in TBS+ 
for 30 min. The primary antibody was applied overnight at 4°C while cells were 
kept in a wet chamber. The next day, cells were washed three times with PBS and 
incubated with the fluorescence conjugated secondary antibody for three hours at 
room temperature. Cells were finally washed three times with PBS and mounted 
onto microscope glass slides.  
Materials and Methods 43 
 
4.2.14. Microscopy 
4.2.14.1. Fluorescence microscopy 
Immunohistochemical preparations were visualized with a fluorescence 
microscope. Fluorescence microscopy was further used to evaluate transfection 
rates. Live cultures were analysed for fluorescence using an inverted fluorescence 
microscope. 
4.2.14.2. Confocal microscopy 
Confocal microscopy was performed using a spectral confocal microscope. 
Immunohistochemical preparations were visualized using three different laser 
channels for FITC (485 nm/535 nm), TRITC (555 nm/575 nm) and Cy5 (650 
nm/665 nm). Appropriate gain and black level settings were determined on control 
tissues stained with secondary antibodies alone. All confocal images were taken 
with a 40 x magnification objective with a keyhole aperture between 45 µm and 85 
µm. Overview images were processed with Photoshop CS and co-localization 
images were processed with Volocity 2.6.1.  
4.2.15. Transfection methods 
4.2.15.1. Electroporation (NucleofectionTM)  
Cells were passaged two to three days before transfection and were growing in 
their logarithmic growth phase. They were washed once with PBS and harvested 
by trypsinization. The reaction was stopped by adding serum containing culture 
medium and cells were centrifuged (800 rpm, 10 min, 4°C). After counting, the 
required number of cells (1 x 106 – 5 x 106 per sample) was centrifuged at 200 x g 
for 10 min at 4°C. The pellet was resuspended in 100 µl room temperature 
NucleofectorTM solution and 1 – 5 µg of the relevant DNA was added. The sample 
was transferred into an Amaxa cuvette, which was inserted into the cuvette holder 
and the appropriate programme was started. Then, 500 µl of pre-warmed culture 
medium was added and the sample was transferred into plates, which were pre-
incubated with medium. The cells were put back to 37°C and the gene expression 
was detectable after 6 – 24 h.  
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4.2.15.2. Lipofectamine transfection 
106 cells/well were plated one day prior to the experiment in a 6-well plate so that 
they reached 90 - 95 % confluency at the time of transfection. For one transfection 
reaction 4 µl of Lipofectamine 2000 was mixed with 250 µl OptiMEM and 
incubated for 5 min at room temperature. Meanwhile, 4 µg of plasmid DNA was 
diluted in 250 µl OptiMEM. Then, 250 µl of diluted DNA was added to each vial 
containing Lipofectamine 2000 and incubated for 30 min. In the meantime, the 
normal growth medium of the plated cells was exchanged for 2 ml/well of 
OptiMEM. The transfection mixture of Lipofectamine 2000 and plasmid DNA 
(500 µl per well) was added to the cells. After six hours, the reagents were 
exchanged for normal growth medium. After two to three days, cells were 
trypsinised, pelleted and plated in an appropriate format.  
 
Vial DNA Opti-MEM I Lipofectamine 2000 Opti-MEM I 
#1 4µg 250µl 2µl 250µl 
#2 4µg 250µl 4µl 250µl 
#3 4µg 250µl 8µl 250µl 
#4 4µg 250µl 12µl 250µl 
#5 4µg 250µl 16µl 250µl 
Control 0 250µl 8µl 250µl 
Table 4.11. Concentration gradient of Lipofectamine 2000 for a transfection 
in a 6-well plate 
4.2.16. G418 sensitivity test 
Prior to the transfection, U373 and GL261 cells were challenged with increasing 
concentrations of G418, from 0,2 – 2,0mg/ml. The minimal concentration of G418 
which was required to kill all the cells after two weeks in culture was taken as a 
sorting concentration for the selection of stable transfectants. In the case of U373 it 
was 1,2mg/ml and 600µg/ml for GL261. Briefly, U373 and GL261 cells were 
trypsinized, centrifuged, counted and plated in 24- well plate at the concentration 
of 2X104cells/well. Then, they were exposed to increasing concentrations of G418 
(see table 2.2.). The medium was changed twice a week. After two weeks in 
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culture, the minimal concentration of G418 enough to kill all the cells was 
established. That concentration was later used as selecting concentration of G418 
for culturing transfected U373 and GL261.  
 
Control- 
no G418 
Control- no 
G418 
0,2mg/ml 
G418 
0,2mg/ml 
G418 
0,4mg/ml 
G418 
0,4mg/ml 
G418 
0,6mg/ml 
G418 
0,6mg/ml 
G418 
0,8mg/ml 
G418 
0,8mg/ml 
G418 
1,0mg/ml 
G418 
1,0mg/ml 
G418 
1,2mg/ml 
G418 
1,2mg/ml 
G418 
1,4mg/ml 
G418 
1,4mg/ml 
G418 
1,6mg/ml 
G418 
1,6mg/ml 
G418 
1,8mg/ml 
G418 
1,8mg/ml 
G418 
2,0mg/ml 
G418 
2,0mg/ml 
G418 
2,2mg/ml 
G418 
2,2mg/ml 
G418 
 
Table 4.12. Distribution of increasing concentrations of G418 in a 24- well 
plate 
4.2.17. Cell Cycle Analysis using FACS analyser 
 For determination of cell cycle progression, the cells were analyzed by flow 
cytometry. The glioma cells were seeded at a density of 5x105 per 60mm tissue-
culture dish. When cultures reached at exponential growth i.e when cells were 80% 
confluent then cells were collected tripsinization, washed twice with PBS, then 
fixed with PBS–methanol (1: 2, volume/volume) solution, and stored at 4°C for at 
least 18 h. After centrifugation, cell pellets were stained with PBS containing 50m 
g/ml propidium iodide (PI), and 50m g/ml DNase-free RNaseA for 30 min at room 
temperature in the dark. The samples were analyzed in a Becton-Dickinson system 
of FACS-Calibur flow cytometer by using CellQuest software. The percentage of 
cell cycle phases (G0/G1, S, and G2/M) was quantified using a ModFit LT 
software. 
4.2.18. Iron Imaging 
Iron measurements were performed using the method by established ( Petrat et al, 
2001). Briefly, Cells plated on glass cover slips were loaded with 20 µm Phen 
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Green SK, diluted in HBSS, for 15 mints at 37°C and then cells were transfererred 
to a perfusion chamber on an upright microscope and fixed in the chamber using 
U-shaped platimum wire. Cells were superfused with Hepes buffer and during the 
perfusion time 5mM chelator (1, 10-phenantroline, Sigma) was applied and 
intracellular Fe+2 changes were detected using a cooled CCD camera resulted in 
an increase in fluorescence. Light source for fluorophore excitation at wavelength 
of 488nm exitation and 505nm emission. Images and evaluation of iron amount in 
single cells was determined by the change in fluorescence and processed with 
conventional software. 
4.2.19. ROS measurement 
Intracellular ROS production was assessed using 2’7’-dichlorodihydrofluorescin 
diacetate (DCFH-DA). DCFH-DA is oxidised by ROS within cells to the 
fluorescent product DCF. Cells seeded in 96 well plate were treated with 50µM of 
dye and incubated at 37°C for 1hr and the fluorescence was measured using 96 
well plate Wallac reader.  
4.2.20. Reporter assays 
A 455bp fragment  of the human TfR promoter region (Owen D and Kuhn LC) 
was cloned in front of luciferase gene and the resulting construct was transiently 
transfected into U373 wild type glioma cells using an electroporaor (Amaxa). The 
activity of pTfR-Luc was compared with mutated TfR promoter constructs in 
which the Ets respectively the AP1, ATF and CREB sites had been altered by site 
directed mutagenesis with the following primers from MWG Biotech. 
The Dual Luciferase assay was used according to manufacturer’s instructions. 
Briefly, cells were seeded at 105 cells per 3.5 cm diameter dish, incubated in 
medium with or without tet for 48 hours, then washed with PBS and agitated 
gently for at least 20 minutes with 500 µl passive lysis buffer. The cell lysate was 
cleared by centrifugation and 20 µl added to 100 µl of luciferase assay reagent in a 
luminometer tube. The relative light units (RLU) were measured immediately in a 
Berthold-2000 luminometer. The average of ten RLU measurements taken at 2-
second intervals was recorded. 
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4.2.21. Western blot 
4.2.21.1. Sample preparation 
Cells were washed two times with ice-cold PBS before the sample buffer was 
applied (10 µl/cm2). Cells were scraped with a rubber policeman and the cell 
lysates were collected in 1.5 ml tubes and incubated on ice for 15 min. Then, the 
samples were centrifuged at 13,000 rpm for 20 min. The pellet was discarded and 
the supernatant collected; the protein concentration was determined using the BCA 
protein assay kit. The protein concentrations of all samples were equalised with 
sample buffer. Mercaptoethanol (5%) and glycerol  
(15 %) was added to the samples and they were incubated at 95°C for 15 min.   
4.2.21.2. SDS-PAGE 
The gels were cast in glass plates. The composition of the gels is shown in tab. 
2.12. Gels were loaded with 10 µl molecular weight marker and 20 µl of each 
sample. Then, electrophoresis was performed at 100 V for 10 min and at 150 V for 
approximately 45 min.  
 
Tab. 4.13. Composition of a 10 % SDS polyacrylamide gel 
Separating gel (lower gel)  
Lower gel buffer 2.5 ml 
Acrylamide 3.3 ml 
12 % glycerol (in H2O) 4.17 ml 
10 % APS 30 µl 
TEMED 15 µl 
Stacking gel (upper gel)  
Upper gel buffer 1.25 ml 
Acrylamide 750 µl 
12 % glycerol (in H2O) 3.0 ml 
10 % APS 20 µl 
TEMED 10 µl 
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4.2.16.2. Semi-dry transblotting 
Gels were carefully removed from the glass plates and equilibrated in transfer 
buffer for 10 min. Meanwhile, a PVDF membrane was activated by incubation in 
methanol for 5 min and afterwards equilibrated in transfer buffer for 5 min. At the 
same time, blotting paper was soaked in transfer buffer and placed on the lower 
electrode (anode). The PVDF membrane and the separating gel were placed 
between two pieces of moist blotting paper. The sandwich was covered with the 
upper electrode (cathode) and blotted at 15 V for  
60 min.  
4.2.21.3. Immunoblotting 
The membrane was incubated in methanol for 5 min, washed once in TBS for 5 
min and then blocked with blocking buffer for 30 min. The primary antibody was 
then added in blocking buffer for an overnight incubation at 4°C on a shaker. On 
the next day, the membrane was washed three times in washing buffer and 
incubated with the HRP conjugated secondary antibody for one hour at room 
temperature. After three more washing steps, each for 20 min, the ECL reagent 
was applied for 5 min. The membrane was dried from excess ECL reagent and 
placed on a transparent foil. It was exposed in a film cassette to ECL films (in the 
dark room) for various time periods (e.g.15 s, 30 s,  
1 min, 5 min) and the films were developed in the film developing machine. 
4.2.22. Oxyblot and detection of oxidised proteins 
To identify carbonyl groups that are introduced into the amino acid side chain after 
oxidative modification of proteins, oxyblot analysis was performed. The derivative 
that is produced by reaction with 2, 4-dinitrophenylhydrazine (DNPH) was 
immunodetected by an antibody specific to the attached DNP moiety of proteins 
using a commercial kit. Briefly, the electrophoresis was performed in the same way 
as described earlier (Castegna A et al, 2002), and the gels were transferred to a 
nitrocellulose membrane using a semidry transfer system. Membranes were then 
blocked and incubated with a rabbit anti-DNP antibody (1:150) for 1 hour at room 
temperature. The secondary antibody incubation was performed using horseradish 
peroxidase (HRP)–conjugated anti-rabbit IgG (1:300) for 1 hour at room 
temperature. The immunoreactivity was visualized by enhanced 
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chemiluminescence using commercial reagents. The kit used for the oxyblot 
analysis is sensitive to detect as little as 10 femtomoles of dinitrophenyl residues.  
4.2.23. Gelatin zymography 
 Activity of gelatinases (MMPs) was analyzed with the gelatin zymography 
procedure (Heussen and Dowdle 1980). Briefly, conditioned media from 
organotypical brain slice cultures or cell cultures or whole slice cultures were 
mixed with sample buffer, and the samples were loaded on 7,5% SDS-PAGE 
containing 1% gelatin (table 2.3). After electrophoresis (4°C, 90V), the gel was 
washed two times 15min in 2,5% Tx-100 washing solution, and incubated 
overnight in developing buffer. Next, the gel was stained for 30min in 0,5% 
Coomassie blue solution and then destained in 40% methanol and 10% acetic acid. 
The gel was wrapped between two foils of cellophane and dried in the gel dryer for 
1h. Enzymatic activity resulted in gelatin degradation, which was directly visible 
as clear bands on the dark blue background. The surface of these clear bands 
directly correlated to the amount of the active gelatinase. The different gelatinase 
types were identified by their corresponding molecular weights.  
 7,5%PAAG, 1%Gelatin 4% (loading) gel 
dd H2O 4,35ml 6,10ml 
20mg/ml gelatin 0,5ml - 
30% Acrylamide 2,5ml  1,3ml 
1,5M TRIS HCl, pH 8,8 2,5ml - 
0,5MTRIS HCl, pH 6,8 - 2,5ml 
10% SDS 0,1ml 0,1ml 
10% APS 0,1ml 0,1ml 
TEMED 35µl 35µl 
Table 4.14. Composition of 1% Gelatin 7,5% SDS Polyacrylamide gels 
4.2.24. Chromatin immunoprecipitation assay 
Chromatin immunoprecipitation (chIP) assays were carried out using a 
commercially available kit the chIP-IT™ Express (Active Motif) according to the 
manufacturer’s instructions. One 30-cm dish of 80% confluent wtU373 cells and 
U373 cells stably expressing etsDN or etsDN + TfR was used for one 
immunoprecipitation (IP) reaction. Cross-linking of DNA proteins was induced by 
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an addition of formaldehyde (1% final concentration) directly to the culture 
medium for 10 min at 37°C. Cells were lysed and DNA in the supernatant was 
sheared by enzymatic digestion for 10 min at 37°C. An aliquot of the digested 
chromatin sample (“input”) was removed for polymerase chain reaction (PCR) 
analysis, and the remainder was used for IPs. Immunoprecipitation was performed 
with 1 µg of Ets1 (C-20) antibody or normal goat IgG that had been precoated onto 
Protein G-magnetic Sepharose beads, and reactions were incubated for 4 h with 
constant rotation at 4°C. Protein G beads were collected using magnetic stand and 
protein DNA complexes were eluted from the beads followed by a cross-link 
reversal step. DNA from each IP reaction (3 µl) was used for PCR with a primer 
pair to amplify the 110-bp region of interest of human TfR gene. Input or 
immunoprecipitated DNA was amplified by PCR (94°C, 20 s; 55°C, 30 s; and 
72°C, 30 s) for 35 cycles. In parallel, chromatin was precipitated with positive 
control antibody (RNA polII) and negative control IgG from the chIP-IT™ control 
kit (Active Motif); then, input and immunoprecipitated DNA was amplified by 35-
cycle PCR with human-specific positive GAPDH primers under recommended 
conditions, generating 166-bp products. All PCR products were resolved in 1.5% 
agarose gels.  
4.2.25. Identification of mRNA transcripts 
4.2.25.1. RNA isolation (RNeasy Mini Kit) 
The cell pellet of glioma was disrupted and the lysate was homogenized in 600 µl 
RLT buffer. After centrifugation (14,000 rpm, 3 min, 4°C) 600 µl of 70 % ethanol 
was added to the supernatant. The sample was applied to a RNeasy mini column 
placed in a 2 ml tube and centrifuged at 10,000 rpm, 15 s, 4°C. The flow-through 
was discarded and 700 µl of buffer RW1 was added to the column. The tube was 
again centrifuged and transferred into a new collection tube. 500 µl of RPE buffer 
was added twice onto the column to wash the sample. After transfer of the column 
to a new 1.5 ml tube, 40 µl of RNase-free water was added onto the membrane. 
After 5 min incubation the tube was centrifuged at 10,000 rpm for 1 min to elute 
the DNA. Finally, the RNA concentration was quantified using a photometer.  
Materials and Methods 51 
 
4.2.25.2. Reverse transcription (RT) – PCR  
To obtain cDNA, which can be used for a PCR reaction, RT-PCR was performed. 
Therefore the following mixture was prepared: 
Oligo-dT 1 µl 
dNTP Mix (10 mM each dATP, dCTP, dGTP, dTTP) 1 µl 
Total RNA 1 µg 
DEPC-H2O ad 20 µl 
 
This was heated up to 65°C for 5 min and quickly chilled on ice. Then, the 
following mixture was added: 
5 x First-Strand buffer 4 µl 
DTT (0.1 M) 2 µl 
RNase OUT Recombinant ribonuclease inhibitor 
(49 u/µl) 
1 µl 
 
The mixture was incubated at 42°C for 2 min and 1 µl Superscript II (200 U) was 
added. Hereon, another incubation at 42°C followed for 50 min and the reaction 
was inactivated at 70°C for 15 min. The cDNA concentration was quantified using 
a photometer.  
4.2.25.3. Polymerase chain reaction (PCR) 
To amplify certain segments of the yielded DNA, PCR reactions were performed. 
Therefore the following reaction was mixed: 
 
Tab. 4.15. PCR reaction mixture 
 10 x PCR buffer 5 µl 
MgCl2 1.5 µl 
dNTP mix 1 µl 
Primer 1 1 µl 
Primer 2 1 µl 
Taq 0.4 µl 
cDNA 5 µl 
H2O 35.1 µl 
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Tab. 4.16. PCR-temperature profiles and number of cycles 
1. Hot start 94°C 1 min 
2. Denaturation 94°C 30 s 
3. Primer annealing  Annealing temperature 30 s 
4. Elongation 72°C 1 min; 35 cycles 
5. End 72°C 8 min 
6. Pause 4°C ∞ 
 
4.2.25.4. Gel electrophoresis of the PCR products 
The PCR products were loaded onto an agarose gel in order to visualize them 
under UV-light using a fluorescence dye. The 3 % agarose gel (in 1 x TAE buffer) 
was cast and pre-stained in SybrGold (1:10,000) for 40 min in the dark. 10 µl of 
each PCR product was mixed with 5 µl loading buffer and loaded into the gel slots; 
a 1 kb DNA ladder was also loaded. Electrophoresis was carried out at a voltage of 
90 V for approximately 45 min. The DNA bands were visualized using the gel 
documentation facility G-Box. 
4.2.25.5. Real time PCR 
Quantitative RT-PCR reactions were run in triplicate using Brilliant® SYBR® 
Green QPCR Core Reagent Kit. SYBR Green dye binds to any PCR product, 
Fluorescent emission was recorded in real-time (Chromo 4 Four-Color Real-Time 
PCR Detector, MJ Research, Bio-Rad). Gene expression profiling was completed 
using the comparative Ct method of relative quantification. Relative RNA 
quantities were normalized to two endogenous controls, GAPDH and 18S 
ribosomal RNA (18S rRNA). 
 
4.2.25.6. Statistical analysis 
Statistical significance was determined at the p < 0.05 level. The results are 
expressed as mean values ± standard errors of the mean (SEM). Comparisons 
among the groups were performed with the Student’s t test. 
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5. Results-Part I: Mechanism of anti-tumorigenic effect of 
endogenous neural precursor cells against glioma 
5.1. Neural precursor cell-derived BMP7 inhibit the tumorigenic potential 
of glioma stem cells 
5.2. Neural precursor cells (NPCs) express BMP7 in tumor (glioma) 
margin 
We have established previously, that endogenous neural precursor cells (NPC) are 
attracted to experimental brain tumors (gliomas) and induce tumor cell death 
(Glass R et al, 2005) and our further hypothesis is that NPC exert an even more 
far-reaching anti-tumorigenic effect by suppressing murine and primary-human 
CD133 positive glioma stem cells (GSC) via release of a soluble factor. A 
previous study by Vescovi et al (Piccirillo, S.G.M., et al 2006) showed that bone 
morphogenic proteins (BMPs) induce the suppression of glioblastoma 
tumorigenicity in vivo and in vitro via the differentiation of CD133 positive glioma 
stem cells. In analogy to the physiological action of BMPs in the brain, which 
induce NPCs to differentiate into mature glial cells (Alvarez-Buylla, A., et al 
2004). Here we investigated whether the endogenous neural precursors express 
BMPs in vivo and detected predominantly BMP7 by immunohistochemistry 
especially in the tumor-margin. In this model, gliomas were induced by injection 
of murine glioma cell line (GL261 which express fluorescent marker) in to a 
nestin-GFP transgenic mouse and clearly observed the localisation of BMP7 in 
NPCs which are very near to the tumor margin area as shown in Fig.5.1. 
Furthermore, I show that NPCs in vitro readily release BMP7 and that GSCs 
respond to NPC-derived BMP7 by undergoing differentiation. 
 
 
Fig. 5.2. Subventricular zone derived, BMP7-expressing NPC migrate towards glioma.  
A transgenic mouse expressing GFP under a modified nestin-promoter was inoculated with 
syngenic glioma cells (GL261 cells) expressing a fluorescent marker. 14 days after the operation 
SVZ-derived NPC have accumulated at the experimental tumor. Confocal micrographs giving an 
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overview on the distribution of BMP7 in NPC at a glioma. Note that in merged fig (extreme right) 
clearly BMP7 is localised in NPCs close to the tumor margin.Scale:100µm. 
 
5.3. BMP7 expression in the glioma margin is predominantly contributed 
by migrating NPC 
After confirming by immunohistochemistry that BMP7 is expressed in tumor 
margin, I asked which subtype of NPCs does express BMP7. We found that mainly 
PSA-NCAM positive NPCs were co-immunolabelled for BMP7, these cells have 
previously been characterised as the migrating type-A cells (García-Verdugo et al, 
1998) nestin-GFP transgenic (p30) was inoculated with glioma cells which 
expressess fluorescent marker and after 14days of operation mouse was sacrificed 
and stained for nestin-GFP, PSA-NCAM and BMP7 in the glioma margin as 
shown in Fig.5.3. Using confocal microscopy overlay images were generated by 
Zeiss ZEN software that showed only the fraction of cells in which two 
immunofluorescence markers co-localised and detected that PSA-NCAM+/nestin-
GFP+ cells predominantly expressed BMP7. 
 
 
 
Fig. 5.3. In the glioma margin, only PSA-NCAM-positive NPC predominantly expressess 
BMP7 
Nestin-GFP transgenic mouse (p30) was inoculated with glioma cells (Gl261) which expresses 
fluorescent marker and after 14 days of operation mouse was sacrificed and processed for 
immunohistochemistry. Co-localisation of nestin-GFP (green), PSA-NCAM (red) and BMP7(blue) 
in the glioma margin was investigated by confocal microscopy. Overlay images (generated by Zeiss 
ZEN software) show only the fraction of cells, in which two immunofluorescence markers co-
localise; note that PSA-NCAM+/nestin-GFP+ cells express BMP7. Scale: 80µm. 
 
5.4. Neural precursors in subventricular zone (SVZ) expressess BMPs 
After having observed the expression of BMP7 in tumor associated neural 
precursor cells it was interesting to know whether NPCs in the stem cell niche also 
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expresses these BMPs. Tissue from nestin-GFP-transgenic mice was 
immunostained for different BMPs, analysis by confocal microscopy showed that 
even in normal adult murine brain expresses BMP2, BMP4 and BMP7, especially 
expression of BMP7 is associated with the NPC which have the migrating capacity 
i.e. which are PSA-NCAM expressing NPCs. Furthermore, BMP2 and BMP4 were 
not found in the tumor margin, but could be detected well in the SVZ as seen in 
Fig.5.4. 
 
 
Fig. 5.4. Neural precursors in subventricular zone(SVZ) expresses BMPs 
 A SVZ explant from a nestin-GFP adult mouse was immunostained for different BMPs and the 
confocal composite image shows the expression of BMP7 association with PSA-NACM positive 
NPC(upper panel) and expression of BMP2 and BMP4 co-localised with nestin in the SVZ region 
(lower panel). Scale bars: 25 µm 
 
5.5. Neurosphere cultures abundantly express BMP7 mRNA 
NPCs were isolated from SVZ region of brain from p30 adult mouse and cultivated 
as neurosheres under standard growth conditions and some NPC cultures were 
subjected to differentian paradigm (diff-NPC) at the same time glioma cells were 
also treated with the same conditions as of normal NPC culturing medium and 
after 3days these cells were pelleted down and isolated mRNA and by using 
realtime PCR analysed the relative expression of different BMPs like BMP1, 2, 3, 
4, 5, 6, 7 and 8b. Vescovi et al showed that recombinant BMP4 effectively 
inhibited glioma stem cell growth but they also reported that recombinant BMP7 is 
almost as efficient (Piccirillo, S.G.M., et al 2006). I discovered that neurospheres 
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highly expressed mRNA for BMP7 and that NPCs lose BMP7 expression when 
undergoing differentiation. Glioma cells(GL) and the subfraction of CD133+ 
glioma initiating cells (GL-CSC) did not significantly express BMPs as shown in 
Fig.5.5. (n=3). 
 
 
 
Fig.5.5. Neurospheres highly express BMP7. 
NPC were cultivated as neurospheres and some cultures underwent a differentiation paradigm (diff 
NPC). Likewise glioma cells (GL261WT) were cultured under conditions used for NPCs. GL-
CSCs, which are CD133 expresing murine glioma stem cells were also investigated, a range of 
BMPs was quantified by real-time PCR n=3. 
 
5.6. PSA-NCAM positive NPC neurosphere cultures express and release 
BMP7 protein 
Neurosphere cultures were grown as mentioned above and analysed. Further, PSA-
NCAM positive and negative NPCs were isolated by using a FACS sorter, these 
cells (along with normal bulk NPCs, differentiated NPC and also along with 
normal primary astrocytes, microglia and neuronal cells) were assayed by ELISA 
for BMP7 expression. 
These assays revealed that BMP7 is much stronger expressed in undifferentiated 
than in differentiating neurospheres and that BMP7 protein is also much more 
abundantly in NPCs than in glia or neurons Fig.5.6.A.  Furthermore, I investigated 
the conditioned medium from undifferentiated neurospheres and observed that 
BMP7 is constitutively released from these cultures Fig.5.6.B.  Furthermore, 
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immunoblot for BMP7 showed the release of BMP7 from total NPC cell lysates 
(Fig.5.6. C). 
 
 
 
Fig.5.6. BMP7 is predominantly expressed in PSA-NCAM+ cells in vitro and BMP7 is 
constitutively released. 
Cultures of astrocytes, microglia, neurons, neurospheres (total NPCs), differentiated NPCs, and 
PSA-NCAM+ cells from neurosphere cultures were analysed for BMP7 expression by an ELISA; 
note that PSA-NCAM+ cells are the predominat cell-type expressing BMP7 in vitro (A), 
Supernatants from neurosphere cultures were analysed for BMP7 by an ELISA assay(B), (n=3). C) 
Shows the immunblot for BMP7 from cells lysates of NPCs. 
5.7. Glioma stemc cells express receptors for BMPs 
To investigate the potential effects of BMPs on glioma stem cells (GSCs) and to 
determine if glioma initiating cells can receive BMP signals, I used RT-PCR 
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analysis from cDNA isolated from human glioma stem cells (GSCs), which are 
more than 95% positive for the glioma stem cells marker CD133. This experiment 
revealed the expression of receptors for BMP receptor type-1a, type-1b and BMP 
receptor type II (Fig.5.7.). 
 
 
Fig. 5.7. BMP receptor expression analysis by PCR from NCH421k cells 
Glioma stem cells (NCH421k) were analysed by RT-PCR for expression of receptors for BMPs like 
BMPtype I and type II receptors as shown in upper panel BMP type Ia , type Ib and type II 
receptors are expressed in NCH421k cells, note that type Ia receptor is highly expressed compared 
to their counter parts typeII receptors, actin loading controls are shown in lower panel. 
 
5.8. BMP-release from neurospheres downregulates CD133 expression in 
Glioma Stem Cells 
After detecting the release of BMP7 from NPCs and further identifying the BMP 
receptors expression in glioma stem cells, I asked whether the conditioned medium 
from NPCs has any impact on the glioma stem cells. Hence I stimulated different 
glioma initiating cells NCH421k cells, a human glioblastoma highly enriched for 
CD133+ cells,  B4-cells were from a human glioblastoma and were maintained 
only for maximally 5 passages in vitro, these cells contained 35% CD133+ cells 
without prior enrichment and also enriched murine glioma stem cells (Gl261). 
Cells were left untreated (Ctrl.) or were treated for 5 days with recombinant BMP7 
(100ng/ml), neurosphere-conditioned medium (CM) and/or a specific BMP-
receptor antagonist (BMPR1a and 1b antagonist) Dorsomorphin (10µM) also 
called compound-C; CC (Yu, P.B. et al 2008)). CD133 expression on the cell 
surface was quantified by FACS. Interestingly, NPC conditioned medium along 
with recombinant BMP7 showed 40% reduction in CD133 count in case of murine 
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glioma stem cell as measured by mean fluorescence intensity, this effect is 
completely reverted by blocking with dorsomorphin (CC) and treatment with 
compound-C alone did not show any effect on the expression of CD133 as shown 
in upper panel of the Fig.5.8.A. 
 
In case of the human glioma initiating cells (NCH421k and B4), NPC conditioned 
medium showed an even more significant effect as the recombinant BMP7 and 
reduced the CD133 count to 50% (as shown in B and C of the Fig.5.8.). Note that 
the addition of recombinant BMP7 to glioma stem cell cultures fully mimicked the 
effect as of conditioned medium, where a specific BMP-receptor antagonist fully 
blocked the effect of NPC conditioned medium. 
 
This gave me a clear hint that the released BMPs in the conditioned medium from 
NPCs might have anti-tumorigenic effect by reducing the CD133 positive glioma 
stem cells. 
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Fig.5.8. BMP-release form neurospheres downregulates CD133 expression in GSCs.  
CD133-enriched (> 80%) Gl261, cells are from a mouse glioma cell lines (A) and NCH241K-cells 
(B) were derived from a human glioblastoma; C) B4-cells were from a human glioblastoma, 
contained 35% CD133+ cells without prior enrichment and were cultivated for maximally 5 
passages. Cells were left untreated (Ctrl.) or were treated for 5 days with recombinant BMP7, NPC 
neurosphere-conditioned medium (CM) and/or a specific BMP-receptor antagonist compound-C; 
CC. CD133 expression on the cell surface was quantified by FACS analyser. In case of Gl261 and 
NCH421k n=3 and in case of B4 n=1, values were represented as meanflourescence intensities. 
 
5.9. Glioma Stem Cells respond to NPC-derived BMP7 
Human glioma stem cells, NCH 421k (primary human glioma cells enriched for 
CD133; i.e. approx. 95% CD133+) respond to exogenous application of 100ng per 
ml recombinant BMP7 and to the NPC conditioned medium by phosphorylation of 
smad1/5/8 as detected by western blotting. NCH 421k cells were treated with 
recombinant BMP7 as wells with NPC conditioned medium (c.m) for 60mints and 
detected high amounts of phospho Smad-1/5/8( it is detected even after 30 mints of 
treatment with recombinant BMP7 Fig.5.9.A) compared to untreated control(no 
treatment). Further, the expression was reversed back to normal levels by using 
compound-C and treatment with compound-C alone did not show any effect on the 
expression of phospho-Smad 1/5/8 levels. As loading controls ß-tubulin was used 
and total Smad 1/5/8 levels were also shown Fig.5.9.B. 
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Fig.5.9. BMP7 signalling in Glioma Stem Cells: Western blotting for Smad1/5/8 showing 
that NCH421k, Human glioma stem cells, respond to NPC conditioned medium and to exogenous 
application of 100ng of recombinat BMP7(A) by phosphorylation of smad1/5/8; ß-tubulin was used 
as a loading control along with total Smad1/5/8 levels(B). 
 
5.10. NPC-derived BMP7 downstream signalling in glioma stem cells 
Next, I wanted to explore whether NPC-derived BMP7 induced phosphorylation of 
Smad 1/5/8 also could induce transcriptional changes of target genes. In this 
regard, the inhibitors of DNA binding proteins (Ids) are considered to be some of 
the major target genes for Smad-signalling. Thus, glioma stem cells were treated 
with NPC conditioned medium (CM) and with recombinant BMP7 alone or in the 
presence of BMP antagonist Dorsomorphin (CC) for 24hrs before preparation of 
total RNA. The amount of Id1 and Id2 mRNA was quantified by real-time RT-
PCR. Interestingly, I observed a nearly 25 fold up-regulation of Id1 mRNA in 
BMP7 treated as well as NPC conditioned medium treated glioma stem cells 
compared to Id2 expression which is nearly 7fold up-regulation in comparison to 
untreated control GSCs and this effect was completely blocked by BMP antagonist 
Dorsomorphin (CC) (Fig.5.10.). 
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Fig. 5.10. NPC-derived BMP7 downstream signalling in glioma stem cells 
Real-time PCR analysis of BMP7 target genes, Id1 and Id2, expression in GSCs treated with BMP7 
and NPC conditioned medium (CM) for 24hrs showed the up-regulation of Id1 and Id2; values are 
normalised to 18S RNA transcript levels and expressed as relative quantification levels. 
 
5.11. BMP7 represses sphere formation of glioma stem cells 
NCH421k cells were kept invitro for 5 days and either cultures without additives 
(control) or treated with recombinant BMP7 (100ng/ml), BMP7 together with the 
antagonist compound-C or with compound-C alone. Then these NCH421k samples 
were re-plated in new (additives free) control medium and the ability for sphere 
formation was observed with different plating densities.  After 14 days in control 
conditions the number of spheres more than >250µm was quantified under a 
microscope by using a graded plastic dish. Interestingly BMP7 treated cells 
showed less ability to form spheres compared to controls cells as well as cells 
blocked with compound-C as shown in Fig.5.11. 
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Fig.5.11. BMP7 represses sphere formation of GSCs. NCH421k cells were treated with 
100ng/ml of recombinant BMP7 and with other conditions as mentioned above, spheres were 
dissociated and varying cell numbers were plated in a 24-well plate (containing normal 
neurosphere medium). After 14 days in vitro the ability for sphere-formation (>250µm) was 
quantified. Values were represented as number of spheres per well per 100cells. 
 
5.12. NPC derived BMP7 elicits a pro-differentiation effect on glioma 
stem cells 
Glioma stem cells were treated with NPC conditioned medium or with 100ng/ml 
recombinant BMP7 for 5 days cells, then the cells were observed under phase 
contrast microscopy. I noticed that the cells treated with C.M. or with BMP7 had a 
more differentiated morphology as compared to the untreated cells (shown in 
Fig.5.12.A). 
I also observed an increase in the expression of astroglial markers (GFAP) 
immunoreactivity (Fig.5.12.C) but reduced nestin immunoreactivity after treatment 
with NPC conditioned medium (Fig.5.12.B) over a period of 5days indicating that 
the released factors from NPCs i.e. BMPs, which generally induce GFAP 
expression and eventually promote astrocytic differentiation, show their anti-
tumorigenic effect though their pro-differentiation effect on glioma stem cells.  
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Fig.5.12. Loss of glioma cell identity though differention effect of NPC-derived BMP7  
A)Phase contrast images showed that BMP7 and NPC conditioned medium induced a differentiated 
morphology in glioma stem cell (NCH421k) spheres; BMP7:100ng/ml, B) reduced 
immunoreactivity of nestin and C) increased GFAP immunoreatctivity after treating glioma stem 
cells for 5days with NPC conditioned medium, values were represented as %of nestin positive cells 
as % of GFAP cells. 
 
5.13. BMP7 supressess the proliferation of glioma stem cells and 
induce cell death 
Next, I investigated the effect of BMP7 on glioma stem cells (NCH421K) treated 
over 5 days on glioma stem cells (NCH421k) which showed a small but significant  
induction of cell death analysed by cytotoxic assay. The same treatment also 
triggered a significant loss of proliferation capacity as indicated by a significant 
decrease in the Ki67 labelling index. 
 
Fig.5.13. Analysis of cytotoxicity and proliferation in BMP7-treated glioma stem cells. 
Over 5 day exposure of BMP7 to glioma stem cells (NCH421k) did not significantly induce cell 
death analysed by cytotoxic assay(B). Conversely, the same treatment triggered significant loss of 
proliferation capacity as indicated by a significant decrease in the KI67 labelling index(A).  
 
5.14. NPC-derived BMP7 inhibits tumorigenicity of glioma stem cells 
and prolongs survival in a mouse model 
Since NPC-derived BMP attenuated glioma stem cell marker expression, I 
investigated if NPC conditioned medium and recombinant BMP7 can also interfere 
with glioma stem cell functions, which are defined by an unlimited capacity for 
self renewal, maintenance of a cellular hierarchy and strong tumor-initiating 
ability. 
I tested the survival of mice inocculated with two different populations of glioma 
initiating cells. The GL261 cells were sorted for CD-133 expression (the 
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population was 80% positive for CD-133). Cells were either treated for five days 
with recombinant BMP-7 and then inocculated in mice. In comparison to classical 
tumor cell injections we only injected 100 cells per animal. The second, control 
group was injected with untreated cells. As shown in Fig.5.14.A the survival of 
mice inocculated with BMP-7 treated cells was significantly longer as compared to 
control. In another experiment I investigated if neurosphere conditioned medium 
would also have an effect on tumor initiation and survival in mice. I added NPC-
conditioned medium with or without the BMP receptor antagonist compound-C to 
NCH421K glioma stem cells, left the cells for five days under these conditions and 
then implanted 100 cells into brains of immunodeficient mice. I observed that 
NCH421K cells that had received neurosphere conditioned medium alone had a 
strongly reduced capacity for tumor-initiation, as compared to human glioma stem 
cells incubated with NPC-conditioned medium plus compound-C as show in 
Fig.5.14B. In the group of NCH421K cells exposed to NPC-conditioned medium, 
six out of twelve mice survived free of symptoms until the end of the study (more 
thean 240 days), whereas all mice receiving NCH421K cells treated with 
neurosphere conditioned medium plus compound-C died within an average time of  
39 days. All differences in survival time were statistically highly significant 
(p<0.001). Further in Fig.5.14.C showed H and E staining for the same mouse 
from condition A brain slice after the survival study of which showed, untreated 
control mouse brain had much more tumor area compared to BMP7 treated one.  
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Fig.5.14. NPC-derived BMP7 inhibits tumorigenicity of glioma stem cells and prolongs 
survival in a mouse model. 
Kaplan-Meier survival analysis: GL261 glioma stem cells (>80% positive for CD133) were treated 
for 5 days with BMP7 or untreated (control) or NCH421k cells with pre-treated NPC-CM or with 
NPC-CM+ Compound-C (CC). 100 viable glioma stem cells were inoculated in to the caudate 
putamen of C57/BL6 mice and postoperative survival was monitored; note that pre-treating GSCs 
with BMP7 or with NPC-CM improves survival (A and B); C shows the H and E staining for the 
mouse from A. 
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6. Results part II:  Cell autonomous molecular mechanism of ets   
transcription factor induced pro-tumorigenic signalling in 
glioma 
 
6.1.Proliferating glioma cells overexpress the Transferrin receptor 
Experimental gliomas were induced by injection of GL261 cells (overexpressing 
GFP) into syngenic mice. A large fraction of the glioma cells massively 
overexpressed the Transferrin receptor (TfR), compared to normal parenchyma 
(Fig. 6.1, A and B). In breast cancer TfRhas been discussed to fulfil growth factor-
like functions (Cavanaugh et al., 1999), therefore we investigated a potential 
growth promoting effect by TfR in gliomas. Mice bearing a glioma in the caudate 
putamen were intraperitoneally injected with a single dose of BrdU into the 
peritoneum 2h before sacrifice. Thereby, I systemically labelled all cells being in 
S- Phase. In the glioma observed that not all TfR+ cells were in S-phase, but 
detected that all BrdU+ cells strongly overexpressed TfR. 
 
Fig. 6.1 (A) Immunostaining for TfR (blue) in an experimental glioma (red) in mice. TfR is 
strongly overexpressed only in the glioma. An area marked by the rectangle was magnified in (B) 
TfR overexpression colocalizes with the glioma cells in the tumor area and on the single cell level; 
a single cell (highlighted by arrow) was 3D reconstructed cell (insert in B). (C) Strong labelling for 
TfR (red) in GL261 glioma cells (expressing GFP) having incorporated BrdU (blue), after systemic 
BrdU administration. 
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6.2. Transferrin receptor overexpression in glioma is regulated via an ets 
transcription factor binding site in the TfR promoter 
First, we confirmed that TfR is overexpressed in the human glioma cell line U373, 
compared to the low-malignancy astrocytoma line 1321N1 and to primary cultured 
astrocytes (Fig.6.2. A). In the same Western blot we show that overexpression of 
an ets1 dominant negative protein (etsDN; Nakada et al., 2001) substantially 
downregulated TfR in U373 cells. TfR expression was rescued in etsDN cells 
transfected to overexpress human TfR (Fig.6.2, A). Next, we screened for further 
transcription factors potentially controlling TfR expression. Therefore, we used a 
luciferase coupled TfR promoter construct containing an overlapping consensus 
sequence for   binding of AP1, CREB and ATF and also an ets binding site 
(Marziali et al., 2002; Owen and Kuhn, 1987). Mutation of the ets binding site 
strongly attenuated TfR expression, whereas mutation of the AP1/CRE/ATF site 
remained largely without effect, arguing that ets transcription factors drive the 
expression of TfR in glioma (Fig. 6.2, B). 
 
 
Fig. 6.2. Overexpression of transferrin receptors is regulated by ets transcription factors in 
glioma 
(A) Western blot showing overexpression of TfR in WT U373 glioma vs. primary astrocytes and 
1321N1 astrocytes, dominant-negative U373 (etsDN) and etsDN+TfR overexpressing U373 
(etsDN+TfR). (B) TfR promoter luciferase-reporter assay in a promoter containing an Ets, Ap1 and 
Cre binding sites (non-mutant) compared to basic vector. Reporter activity is reduced after mutation 
of the Ets binding site (m-EBS) but not after mutation of Ap1 and Cre sites (m-Ap1 and m-Crem).  
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6.3.Trancription factor ets1 directly binds to the promoter region of the TfR 
gene 
A chIP revealed that ets1 directly binds to the promoter region of the TfR gene 
(Fig. 6.3, A ). Ets1 binding is seen only in WT cells (see arrow in Fig. 6.3, A) and 
is prevented in etsDN-expressing cells. These data show that etsDN overexpression 
directly blocks ets1 function. Western blotting for a phosphorylated (and therefore 
hyperactivated) form of ets1 in nuclear and cytosolic fractions of U373 cells 
(Fig.6.3, B) indicated phosphorylation of ets1 in WT cells, which was attenuated 
by etsDN expression. However, forced expression of TfR rescued the 
phosphorylation of ets1 in etsDN-expressing cells, suggesting a positive feedback 
signal from TfR for ets1 activation. 
 
Fig.6.3.  Chromatin immunoprecipitation assay showing the binding of ets1 to the promoter 
region of TfR gene 
WT, etsDN, or etsDN + TfR cells were taken for chromatin immunoprecipitation assays, either 
using an anti-Ets1 (C-20) antibody or an unspecific IgG (Neg IgG) as a control. Total cell lysates 
were used as a positive control (input). The specific PCR product is a 110-bp sequence of the 
promoter region of the TfR gene. Positive chIP is indicated by an arrow (A). A control 
immunoprecipitation and PCR reaction with GAPDH primers was carried out in parallel on WT 
cells (right panel). B. Western blotting for phosphorylated ets1 on nuclear and cytosolic fractions of 
WT, etsDN, and etsDN-TfR cells; cross-reactivity of an ets1 antibody with annexin-V was used as a 
loading control. 
6.4. Alteration in expression of transferrin receptors in glioma changed 
their morphology 
The morphology of wild type U373, U373 EtsDn and U373 etsDn+TfR cells 
cultured on cover slips are compared, wild type and transferrin receptor over 
expressing cells are exhibited round morphology where as EtsDn cells showed 
spindular morphology.  Further, I observed under time lapse fluorescence 
microscopy (in 20X magnification for 20mints perfusion) that WT and etsDn+TfR 
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are morphologically very dynamic, frequently showing membrane expulsions, 
intrusions and high cell motility. Moreover these showed active lamellipodia and 
philopodias where the opposite was observed in etsDn cells, these cells seems were 
much less dynamic and largely remained in a elongated shaped with very little 
cellular movement and severe changes in plasma membrane morphology. 
 
 
Fig. 6.4. Alteration in expression of transferrin receptors in glioma changed their 
morphology. Cells of wild type glioma (U373), dominant negative form of ets expressing cells 
(etsDn) and transferrin receptor over expressing etsDn cells (U373 etsDn+TfR) cultured on 
coverslips were observed with phase contrast microscope under 20X magnification, where the cells 
of typical glioma U373 showed active lamellipodia and philopodias with round shape the same 
observed in U373 etsDn +TfR but this is not observed in etsDn cells. 
6.5. Over expression of transferrin receptors in glioma is independent of 
culture conditions  
 Further, we observed that TfR expression is also largely independent of the culture 
conditions and hypoxia mediated Hif1 function. In an additional experimental 
approach we cocultured etsDN expressing U373 cells together with wild-type cells 
ensuring that both cell types grow identical conditions, especially with respect to 
the iron content in the culture. In these cocultures only the wild-type cells 
overexpressed TfR as shown by immunocytochemistry (Fig.6.5.). 
 
Fig.6.5. TfR expression in glioma in vitro is not altered by the culture conditions 
Ds-Red expressing U373 cells strongly immuno-labelled for TfR (arrowhead) while GFP 
expressing EtsDn cells show low TfR levels in the same culture; note TfR localisation in a 
magnified image (rectangle).  
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6.6. TfR expression in glioma in vitro is not altered by hypoxia and Hif1 
Under hypoxic conditions or during iron deficiency TfR expression may be 
induced by the transcription factor Hif1α, which can also bind to the DNA stretch 
used in our reporter gene assay (see above). However TfR expression did not 
change under hypoxic conditions (5% Co2, pO2<0.2hpa, for 24h) and after 
pharmacological inhibition of Hif1α with YC1 (Sun et al., 2007) in hypoxic 
glioma. The corresponding controls show that hypoxia induced and YC1 
efficiently blocked accumulation of nuclear Hif1α. Hypoxic U373 cells also had 
higher Hif1α activity as measured with a luciferase based reporter construct 
containing Hif1 binding sites. 
 
 
Fig.6.6. TfR expression in glioma in vitro is not altered by hypoxia and Hif1 
A) Immunoblot for TfR from U373 WT cells subjected to normoxia or hypoxia for 24hrs, with and 
without the HIF-1 blocker YC1; note that TfR expression is independent of hypoxia or Hif1. (B) 
and (C) showing nuclear localisation and activity of HIF-1 in U373 WT cells under normoxia or 
hypoxia for 24hrs, with and without HIF-1; note that hypoxia enables Hif1 function that can be 
blocked by YC1. 
6.7. TfR expression in glioma in vitro is largely independent of the cellular 
iron concentration, but depends on the oxidant levels 
Western blotting for TfR from U373 cells cultivated under control conditions or 
together with the iron chelator desferroxamin (DFO; 200µM, for 24h) or the iron 
donor ferric ammonium citrate (FAC; 50µg/ml, for 24h) revealed unchanged levels 
of TfR expression (Fig. 6.7. A). Whereas under physiological conditions the 
expression of TfR is regulated in a complex fashion on the transcriptional 
(Marziali et al., 2002; Sieweke et al., 1996) and post-transcriptional (Owen and 
Kuhn, 1987) level.  
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Transcription factors besides ets factors and also the cellular iron level had no 
major effect on TfR expression, but oxidants induced TfR expression. Application 
of H2O2 (50µM, for 24h) further increased TfR expression in U373 WT cells, 
whereas the anti-oxidant N-acetylcystein (NAC; 200µM for 24h) reduced TfR 
protein expression (Fig. 6.7.B).  
 
 
Fig.6.7. TfR expression in glioma in vitro is largely independent of the cellular iron 
concentration, but depends on the oxidant levels 
A) Immunoblot reveals no change of TfR expression in U373 WT cells exposed to the iron chelator 
deferoxamine (DFO) or the iron donator ferric ammonium citrate (FAC), (B) Western blot showing 
altered TfR expression upon treatment of U373 WT cells with the oxidant scavenger N-acetyl 
cysteine (NAC) and the oxidant hydrogen peroxide (H202). 
6.8. Ets transcription factors control Transferrin receptor mediated redox 
signalling 
Next, we addressed whether the ets mediated increase in TfR expression had 
physiological consequences like increased intracellular iron accumulation and 
increased oxidant production by the labile iron pool (Zecca et al., 2004). We 
clonally expanded U373 glioma cells that were derived from wild type (WT) cells, 
from cells containing a tetracylin inducible etsDN construct and from cells 
expressing etsDN plus the human TfR (etsDN+TfR). For iron and reactive oxygen 
species (ROS) measurements and BrdU assays with these cells we averaged data 
obtained from three individual clonal lines.  
 
Tetracycyclin induced expression of etsDN (etsDN-TetON) in U373 cells strongly 
attenuated intracellular iron accumulation, when compared to WT and etsDN cells 
without tetracyclin (etsDN-TetOff), as measured by iron imaging using 
PhenGreen-SK as an indicator (Petrat et al., 2001). In etsDN+TfR cells 
intracellular iron accumulation was fully rescued (comparable to WT; Fig. 6.8. A).  
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EtsDN-TetOn substantially reduced ROS levels in U373 glioma, as compared to 
WT and etsDN-TetOff, which was evaluated by ROS-imaging using DCFH-DA as 
an indicator (Mattia et al., 1993). Reexpression of TfR in etsDN cells fully restored 
iron accumulation in glioma (Fig.6.8. B). FACS analysis of DCFH-DA 
fluorescence in revealed that ROS levels specifically in the estDN-TetOn cells 
were homogenously diminished throughout the whole cell population (Fig. 6.8. C).  
We had shown in our first series of experiments that TfR expression was increased 
after rising oxidant levels. The finding that increased TfR expression mediates 
increased oxidant levels offers the possibility that TfR enhances its own 
expression.   
In BrdU incorporation assays proliferation was decreased in etsDN-TetOn cells as 
compared to WT, etsDN-TetOff and etsDN+TfR cells (Fig. 6.7. D). The 
proliferation of U373 cells directly depended on iron and ROS levels since DFO 
and the NAC largely attenuated glioma proliferation (Fig. 6.8. E).  
Further, we compared the results in the U373 glioma line with those of the low 
grade astrocytoma line 1321N1. These cells constitutively had a significantly lower 
iron content, ROS levels and proliferation rate as compared to U373 cells. 
Overexpression of TfR in the 1321N1cells increased all three parameters (iron 
accumulation, oxidant production and excessive growth) as shown in Fig. 6.8.  
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Figure: 6.8. Induction of transferrin receptor mediated redox signalling is a central proto-
oncogenic function of ets-factors, leading to accelerated glioma growth. 
Intracellular iron content, ROS production and proliferation was measured in U373 (WT) cells, 
tetracycline inducible etsDN expressing U373 cells (etsDN), TfR overexpressing etsDN U373 
(etsDN+TfR) cells and a low malignancy astrocytoma with and without forced TfR expression 
(1321N1- TfR respectively WT). (A) High intracellular iron levels are observed in U373 cells 
having intact ets signalling or in U373 etsDN cells overexpressing TfR, but not in U373 cells 
expressing etsDN alone. Higher intracellular iron accumulation was also measured in 1321N1 cells 
overexpressing TfR compared to WT 1321N1. (B) Similarly, high oxidant levels were measured in 
U373 cells with intact ets signalling or in TfR overexpressing etsDN cells, but not in U373 cells 
expressing etsDN alone; additionally high oxidant generation was observed in TfR overexpressing 
1321 cells. (C) Flow cytometry revealed increased oxidant levels in U373 cells with high TfR 
expression were homogenous throughout the cell populations. (D) BrdU incorporation assay for 
showed high proliferation levels in U373 cell having intact ets signalling or in U373 etsDN cells 
overexpressing TfR, but not in U373 cells expressing etsDN alone; proliferation was also 
drastically increased after TfR overexpression in 1321N1 cells. (E) Levels of BrdU incorporation in 
U373 WT cells are strongly decreased after iron (DFO) or oxidant (NAC) chelation.  
6.9. The Transferrin receptor rescues clonal growth in etsDN glioma 
The role of oxidant production and ets factors for cancer cell proliferation is also 
highlighted by another observation: U373 cells constitutively expressing etsDN do 
not grow at clonal level, i.e. clonal etsDN cells could only be generated by a 
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conditional expression system. However, when we overeexpressed TfR in bulk 
etsDN cultures we grow these cells at clonal density (not shown).  
Overall, we showed that downregulation of TfR expression by attenuating ets 
activity decreased intracellular iron accumulation and redox levels in glioma. The 
generation of reactive oxygen species is catalyzed by excess intracellular iron and 
contributes to brain pathology (Zecca et al., 2004) and high oxidant levels can 
promote cancer cell proliferation (Hussain et al., 2003). Importantly, when we 
rescued TfR expression in etsDN cells we found that these glioma cells re-
established not only iron and oxidants but also cell proliferation comparable to the 
levels in wild type cells. These data show for the first time, that modulation of 
redox signalling is an important pro-tumorigenic effect that can be initiated by ets 
transcription factors.  
6.10.LMW-PTP is a target of ets/TfR mediated oxidation 
After establishing that high proliferation levels in gliomas are maintained by ets-
driven TfR overexpression and subsequent iron accumulation and ROS generation 
we investigated which molecules downstream of ROS mediate signals for the 
accelerated cell division rate. Hence, we searched for proteins, which are known to 
transduce growth signals and which are sensitive to ROS. Therefore, we 
electrophoretically separated whole protein contents of U373-WT, U373-estDN 
and U373-etsDN+TfR and in parallel performed an immunoblotting procedure for 
the detection of oxidised proteins (Oxyblot). From the blots we identified bands 
containing high amounts of differentially oxidised proteins among our cell lines. 
The corresponding bands were excised from gels separating the total protein 
contents of glioma cells and were analysed by mass spectrometry. With this 
procedure We identified low molecular weight protein tyrosine phosphatase 
(LMW-PTP; Chiarugi et al., 2004; Ostman et al., 2006) as a potential target for 
ROS mediated growth signalling (Fig. 6.10.A& B). 
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Fig. 6.10. Identification of ROS target proteins by mass spectrometry. 
(A) Protein contents of WT etsDN-TetOn and etsDN+TfR cells were electrophoretically separated 
(total protein). (B) In parallel we performed an immunoblotting procedure for the detection of 
oxidised proteins (Oxyblot). From the blots we identified bands containing high amounts of 
differentially oxidised proteins among our cell lines. The corresponding bands were excised from 
gels separating the total protein contents of glioma cells and were analysed by mass spectrometry. 
One of the proteins in this band was identified by Maldi-MS as low molecular weight protein 
thyrosine phophatase (LMW-PTP). 
The total amount of LMW-PTP expression was increased in U373-WT and U373-
etsDN+TfR cells compared to U373-estDN (Fig. 6.10.1, A). However, LMW-PTP 
was also differentially oxidised (and hence inactivated) in these three lines. In cells 
with high TfR and ROS content (U373-WT and U373-etsDN+TfR) we detected 
much higher amounts of oxidised LMW-PTP than in U373-estDN (containing low 
TfR and ROS levels; Fig. 6.10.1, B).  
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Fig. 6.10.1 LMW-PTP as a target of Ets/TfR mediated oxidation 
(A) Total expression of LMW-PTP is higher in WT and etsDN+TfR cells compared to etsDN-TetOn 
cells. (B) Immunoprecipitation of equalized amounts of LMW-PTP (input) with the oxyblot system 
(IP: oxidised proteins) and immunoblot for LMW-PTP (blot: LMW-PTP), note that the amount of 
oxidised LMW-PTP is much higher in WT and etsDn+TfR cells as compared etsDN-TetOn. 
 
Importantly, we observed that oxidation of LMW-PTP can account for the 
increased proliferation in cells with high ROS content (Fig. 6.10.2). 
Overexpression of a dominant negative form of LMW-PTP in which the catalytic 
site of the enzyme is inactivated and which therefore mimics the oxidised form of 
LMW-PTP (Giannoni et al., 2006) rescues proliferation in etsDN-TetOn cells. This 
suggests, that the high redox levels in glioma may facilitate growth factor 
signalling in the brain tumors, partly through oxidising LMW-PTP. 
 
 
Fig. 6.10.2 BrdU proliferation assay: BrdU incorporation assay showing the proliferation of U373 
EtsDN cells compared to U373 etsDN cells overexpressing a mutated (catalytically inactive) LMW-
PTP and compared to (WT) U373 cells; note that the mutant LMW-PTP rescues proliferation in 
U373 etsDn cells 
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6.11.Pro-proliferative signalling via Akt is restricted to glioma cells with 
high ROS content 
Next, we sought to establish if U373-WT and U373-etsDN+TfR have altered 
MAPK and Akt signalling compared to U373-etsDN cells. Indeed, cells with high 
TfR levels like U373-WT, U373-etsDN+TfR and U373-etsDN cells without 
tetracyclin exhibited high levels of phosphorylated Akt indicating the activation of 
the Akt pathway. Conversely, cells with low iron and ROS levels like tetracyclin 
stimulated U373-etsDN and DFO or NAC treated U373-WT cells had lower levels 
of phosphorylated Akt (Fig. 6.11.A). However, the total Akt levels in U373-etsDN 
were even increased compared to all other cells, suggesting some compensatory 
mechanism in these glioma cells, e.g. to cope with low levels of Akt 
phosphorylation under low ROS conditions. Akt signalling in U373 cells was 
Pi3Kinase dependent as indicated by the inhibition of phosphorylated Akt levels 
by wortmannin (Fig. 6.11. B). 
 
 
Fig. 6.11. Pro-proliferative signalling via AKT is restricted to glioma cells with high ROS 
content 
We compared the activity of the Akt signalling by Western blotting in U373 (WT), U373 etsDn 
(etsDN) and etsDN+TfR U373 (etsDN+TfR) cells and investigated the effect of altered redox 
signalling.  
(A) Levels of active Akt (phopho-AKT; P-Akt) compared to total AKT expression (Akt) in the 
various U373 cell lines; note that P-Akt is reduced after tetracyclin induced etsDN expression and 
after iron (DFO) and ROS (NAC) chelation, but remains high in all other cells. (B) P-AKT levels 
are reduced after application of the PI3 kinase blocker wortmannin. 
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6.12.Pro-proliferative signalling via MAPK is also restricted to glioma 
cells with TfR overexpressing glioma cells 
Similar to the findings obtained for Akt phosphorylation we observed that all three 
major MAPK pathways are phosphorylated in cells with high iron and ROS 
content (WT, etsDN+TfR) and that tetracyclin induced expression of etsDN and 
subsequent attenuation of ROS generation abrogated MAPK signalling (Fig. 6.12). 
Importantly, TfR overexpressing cells showed increased activation 
(phosphorylation) of p38, ERK and JNK MAPKs, but the expression of total (non-
phosphorylated) MAPKs was at equal level in all three cell lines or even increased 
in the etsDN expressing glioma. This indicates that etsDN only interferes with 
MAPK signalling but does not attenuate MAPK expression. 
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Fig. 6.12. Pro-proliferative signalling via MAPK is restricted to glioma cells with TfR 
overexpressing glioma cells. 
We compared the activity of the MAPK signalling by Western blotting in U373 (WT), U373 etsDn 
(etsDN) and etsDN+TfR U373 (etsDN+TfR) cells and investigated the effect of altered redox 
signalling. 
MAPK ( A.p38, B.Erk and C.JNK) are inactive (non-phosphorylated; P-p38, p-Erk, P-JNK) after 
tetracyclin induced etsDN expression in U373 cells, but expression of total MAPK is not affected; 
note that MAPK signalling is rescued in etsDN cells after TfR overexpression (etsDN+TfR). 
 
6.13.Effect of altered redox signalling on G1 checkpoint control and cell 
cycle progression 
Altered Akt and MAPK signalling can impact on cell proliferation through 
phosphorylation of pRB (Nath et al., 2003) and through phosphorylation and 
translocation of p21(cdkn1a/waf1/cip1) from the nucleus to the cytosol, which inactivates 
p21 (Zhou et al., 2001). In TfR overexpressing glioma pRB was over-
phosphorylated and therefore inactivated (Fig. 6.13. A). Likewise, p21 had a 
predominantly cytosolic localisation in glioma cells with high TfR expression, 
active iron accumulation and abundant ROS generation (Fig. 6.13. B and C& D). 
By quantification of p21 localisation in the respective cell lines we observed that 
95% of all WT cells exhibited cytosolic p21, only 19% of all tetracyclin treated 
etsDN-TetOn had cytosolic p21 localisation (consequently 81% of p21 was 
nuclear) whereas etsDN+TfR had again cytosolic p21 in 89% of all cells. 
The tumor suppressors p21 and pRB control cell cycle entry in G1 and prevent 
cells from entering S-phase. To investigate if p21 and pRB activation in the TfR 
overexpressing gliomas can account for the increased proliferation of these cell 
lines we quantified cell cycle phases in our glioma cell lines by FACS analysis, 
measuring ploidity of the cellular DNA with propidium iodide. We observed that 
in U373-WT and U373-etsDN+TfR the amount of cells, which had entered S-
phase was approximately 50% higher than in tetracyclin stimulated U373-etsDN 
glioma cells. These data indicate that TfR overexpression can facilitate S-phase 
entry and proliferation of gliomas (Fig. 6.13. E). 
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Fig.6.13. Effect of altered redox signalling on G1 checkpoint control and cell cycle 
progression. 
A) Phosphorylation of the RB protein (P-RB) is absent after tetracyclin induced etsDN expression, 
whereas pRB is strongly phosphorylated (inactivated) in U373-WT and U373-etsDN+TfR cells. 
Likewise, (C) p21 is active (nuclear localisation) after tetracyclin induced etsDN expression, but 
(B) inactive (cytoplasmic localisation) in U373-WT and U373-etsDN+TfR cells (loading controls 
are for cytoplasm: actin; for nuclear fraction: TATA-binding protein; TBP). (D) Immunostaining 
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also identifies nuclear localisation (nuclei are blue) of p21 (red) in U373-WT and U373-etsDN+TfR 
cells, but cytoplasmic p21 in tetracyclin induced etsDN cells.  
(E) Cell cycle analysis for WT, etsDN and etsDN+TfR U373 cells by flowcytometry using 
propidium iodide staining; note that in WT and etsDN+TfR the number of cells entering S-phase is 
twice as high as after tetracyclin-induced etsDN expression. 
6.14.TfR mediated, pro-proliferative redox signalling accelerates glioma 
growth in vivo 
To examine if the TfR mediated increase in iron accumulation, redox signalling 
and cell cycle acceleration had direct consequences for the progression of glioma 
in vivo we subcutaneously implanted the WT cells, U373 cells overexpressing 
etsDN and the etsDN+TfR expressing glioma line in immune-compromised mice 
and monitored tumor growth over 8 weeks. Additionally, I examined if the 
application of DFO or NAC in the drinking water had a therapeutic effect against 
glioma cell growth. The tumor sizes were determined weekly. We observed that 
glioma with high TfR activity had the strongest growth over the whole time-course 
examined, whereas iron chelation by DFO greatly reduced tumor growth. In U373 
cells overexpressing etsDN we detected only little tumor growth during the 8 
weeks of the experiment. Most striking therapeutic results we obtained with the 
ROS chelator NAC, which reduced in vivo glioma growth almost to the level of 
etsDN expressing cells (Fig. 6.14. A).  
Next, I compared the tumor sizes we had obtained by volumetric measurement 
over time with the actual tumor mass at the end point of our experiment. Animals 
were sacrificed 8 weeks after glioma cell injection and the tumor was isolated. 
Again the TfR overexpressing cells and glioma with active iron accumulation and 
redox signalling (U373-WT and U373-etsDN+TfR) had significantly increased 
tumor weights compared to U373 expressing etsDN and DFO or NAC treated 
glioma (Fig. 6.14. B). The reduced tumor growth after systemic abrogation of high 
iron and ROS levels by applying an iron chelator or an anti-oxidant to glioma 
bearing mice, further indicated the relevance of redox signalling for glioma 
progression.  
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Fig. 6.14.TfR mediated redox signalling accelerates glioma growth in vivo. 
(A) Tumor growth of subcutaneously implanted U373 WT, etsDn and TfR+etsDn glioma in nude 
mice was followed over a time course of 8 weeks. Additionally, DFO and NAC were given with the 
drinking water to nude mice implanted with WT cells. Glioma grew rapidly in WT and etsDN+TfR 
implanted mice, but progressed much slower in etsDN inoculated animals or in mice receiving DFO 
or NAC. (B) Finally, the tumors were resected from the mice and glioma masses were measured by 
weighing the resections; note that tumor masses  are much higher in WT and etsDN+TfR implanted 
mice, but significantly lower (p<0.001) in etsDN inoculated animals or in mice receiving DFO or 
NAC with the drinking water. 
6.15.Redox signalling upregulates the expression of Matrix 
metalloproteases  
 After establishing that high proliferation levels in gliomas are maintained by ets-
driven TfR overexpression and subsequent redox signalling. I investigated if ets-
induced TfR expression may also activate mechanism that can facilitate the 
expression of the growing tumor mass. Especially, I investigated if ets induced TfR 
may promote glioma invasion and neuronal excitotoxicity. Since gliomas grow in a 
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confined area (growth is ultimately limited by the skull) the tumor actively kills 
surrounding neurons. Additionally, single glioma cells can escape from these 
necrotic areas by deeply invading into the parenchyma.  
To explore if ets and TfR may have a central role for glioma pathway by 
promoting and co-ordinating tumor growth and expansion of the tumor mass, I 
investigated metalloprotease expression (driving invasion) and glutamate secretion 
(causing neurotoxicity) in my glioma model. 
Therefore, conditioned media from cultures of U373-WT, U373-etsDn and U373-
EtsDn+TfR were analysed for the activity of gelatinises by gelatin zymography 
and a prominent band was observed in the range of approximately 65kDa in 
transferrin over expressing cells compared to faint bands in case EtsDn cells 
indicating the stronger activity of MMP-2 correlating with TfR over expression 
along with increased levels of free iron and ROS (Fig 6.15.).  
 
Fig.6.15. Redox signalling upregulates the expression of Matrix metalloproteases  
Gelatin zymography showing the MMP2 activity in WT U373 glioma, dominant-negative U373 
(etsDN) and etsDN+TfR, note that MMP2 activity is much higher in WT and etsDN+TfR. 
6.16.TfR expression in glioma induces glutamate secretion and 
subsequently excitotoxic neuronal death  
We had initially found that TfR expression is independent of iron regulatory 
proteins (IRPs). However, IRPs have a dual role and acquire aconitase activity 
when iron concentration is high (Hentze et al, 1996). Under high iron conditions 
this enzyme has a key role in the biosynthesis of glutamate (McGahn et al, 2005). 
Hence, we investigated whether the expression level of TfR is linked to glutamate 
release activity. Indeed, we found glioma cells with a high expression level of TfR, 
namely U373-WT and U373-etsDN+TfR released large amounts of glutamate into 
the supernatant. Glutamate levels reached 400 to 500µM within 8h a plateau value 
of approximately 700µM within 72h. In contrast, glioma cells with low level of 
TfR expression, the U373-etsDN, released only 15µM glutamate within 8h and 
approximately 50µM within 72h (fig 6.16.D). 
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To study the pathological impact of the glioma derived glutamate, we co-cultivated 
the tumors with hippocampal neurons. In the presence of U373-WT and U373-
etsDN+TfR, we observed massive neuronal degeneration, i.e. the majority of 
hippocampal neurons (more than 80%) had drastically shortened or even 
fragmented dendrites. This effect was almost fully reversed (to about 15% of 
neurons with morphological changes) in cultures treated with an NMDA receptor 
blocker (1µM MK801) or in glioma with little TfR signalling and low iron content 
(U373-etsDN). Likewise, the total number of neurons was reduced in co-cultures 
with U373-WT and U373-etsDN+TfR gliomas (by about 45%), compared to 
U373-etsDN, U373+MK801 and neurons alone (fig 6.16.C) 
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Fig.6.16. TfR overexpressing U373 gliomas induce excitotoxic neuronal death.  
(A, B) MAP2 staining of hippocampal neurons cultured for 24 hours under control conditions or 
co-cultivated with U373 cells. (A) Control neurons without U373 cells have numerous and 
elongated dendrites without dendrite fragmentation. (B) In the presence of U373 cells, hippocampal 
neurons display a strongly altered dendrite morphology. The majority of neurons have short (if any) 
dendrites, often characterized by dendrite fragmentation. Astersisks denote neurons that were not 
classified as degenerating. (C) Quantification of the fraction of neurons with abnormal dendrite 
morphology cultured under different experimental conditions; note that neurons degenerate only in 
co-culture with TfR overexpressing glioma and that their degeneration is prevented by the 
glutamate-receptor (NMDA-receptor) antagonist MK801. Likewise, the total number of MAP2-
positive neurons declines specifically in co-culture with TfR overexpressing glioma, this neuronal 
loss is prevented by MK801. (D) Time-course experiment quantifying glutamate release from U373 
glioma, note that excessive glutamate release is restricted to TfR overexpressing glioma. 
Significance levels (Student’s t-test and ANOVA) are indicated as P<0.05 (*) and P<0.001 (***). 
Scale bar: 100 µm.   
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7. Discussion 
I. Mechanism of the anti-tumorigenic effect of endogenous neural 
precursor cells against glioma 
In the first part of my thesis I elucidated a molecular mechanism of the anti-
tumorigenic effect of endogenous neural precursor cells against glioma. Recently, 
our group has discovered that endogenous precursor cells are attracted to 
experimental brain tumors and mediate an anti-tumorigenic effect by inducing 
glioma cell death (Glass, R. et al, 2005 and Walzlein, J.H. et al 2008). Here I 
provided evidence that the endogenous neural precursor cells show an additional 
anti-tumorigenic effect by suppressing glioma initiating cells (glioma stem cells, 
GSCs) via release of soluble factors like BMP7. 
Neural stem and precursor cells in the adult brain are restricted to stem cell niches 
like the subventricular zone (SVZ) and hippocampus ( Alvarez-Buylla, A., et al 
2004). In addition to their role in brain plasticity, NPCs contribute to brain repair 
after injury (Hallbergson, A.F., et al, 2003). However, genetic mutations can 
transform NPCs into extremely aggressive primary brain tumors, such as glioma 
(Holland, E.C., et al 2000 and 2001). Glioma patients have an average survival 
time of about one year after diagnosis. Current treatment strategies are designed to 
target the bulk tumor mass and potentially fail to suppress an aggressive sub-
population in gliomas, the so called glioma stem cells (Singh, S.K., et al 2004). 
Aggressive and recurrent glioblastomas have been shown to contain a fraction of 
multipotent cells with extensive self-renewing properties that are likely to drive 
tumor growth and a recent discovery of neural stem cell-like tumor cells, termed 
glioma stem cells, in GBM has created a paradigm shift in brain tumor research 
these cells arise from a single, self-renewing cell type, which then gives rise to the 
rest of the tumor, including a variety of more differentiated cell types (Singh et al., 
2003)
These glioma stem cells can be identified, since they express the cell surface 
glycoprotein CD133. It is now under intensive debate that a successful glioma 
therapy may have to target these CD133-positive glioma stem cells. Recently it 
was disovered that recombinant BMP4 can suppress gliomas by specifically 
targeting glioma stem cells (Piccirillo, S.G., et al 2006), similar anti-tumorigenic 
effects against glioma stem cells have been reported using BMPs by an another 
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independent study (Lee., J et al 2008). During development and in postnatal 
neurogenesis BMPs induce NPCs to differentiate into mature glial cells (Alvarez-
Buylla., et al 2002). This pro-differentiative role of BMPs in neural stem cells 
prompted us to study their roles in putative glioma stem cells. 
7.1. Neural precursor cells express and release BMP7 to inhibit 
tumorigenic potential of glioma stem cells 
To investigate further in this direction I asked by which way endogenous NPCs 
show their anti-tumorigenic activity towards gliomas and I have identified a NPC 
released, soluble factor which drastically reduces the amount of CD133 positive 
cells in glioma cultures of murine (GL261) and human origin (primary cultured 
patient material). I observed that NPC conditioned medium reduced CD133 
positive glioma cells by about 50%. This effect was seen in bulk glioma cultures 
and in CD133 enriched cultures (containing approximately 90% glioma stem 
cells). Suppression of the CD133 positive cells seems to occur via induction of 
glioma stem cells to differentiate and also through significant induction of cell 
death. Further, in vitro the glioma stem cell suppressing factor BMP7 was 
identified by Western blotting, real-time PCR and ELISA. In vivo, I investigated 
BMP7 expression by immunohistochemistry and detected BMP7 in the tumor-
margin, where it was located in PSA-NCAM-positive NPCs. Furthermore, I 
showed in cell culture that BMP7 is much more abundant in PSA-NCAM positive 
NPCS than in PSA-NCAM negative NPCs, that NPCs express much more BMP7 
than bulk glioma or glioma stem cells and NPCs constitutively release BMP7. 
FACS analysis indicated that recombinant BMP7 and NPC-conditioned medium 
significantly reduced the number of murine and human GSCs. This effect was seen 
in bulk glioma cultures and in GSC-enriched cultures. Compound-C (CC, also 
known as dorsomorphin - a specific BMP-receptor antagonist) fully blocked the 
effect of recombinant BMP7 and NPC-conditioned medium. Importantly, I found 
that BMP7 release from NPCs suppresses the stem cell functions of GSCs: NPC-
conditioned medium and rBMP7 suppressed GSCs in a sphere formation assay. 
Glioma stem cells generally show their strong ability to initiate tumor by their self-
renewal and proliferation properties. Down regulation of undifferentiated markers 
like nestin and CD133 and up-regulation of differentiation markers like GFAP 
indicates the loss of glioma stem cell self renewal capacity. Importantly, NPC-
derived BMP reduced the tumorigenic potential of glioma stem cells, which is 
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basically defined by their ability to form tumors from a very small number of cells 
and by unlimited self renewal. Firstly, BMP in NPC-conditioned medium 
suppressed sphere formation and expansion of GSCs in a sphere formation assay.  
Secondly, recombinant BMP7 and BMP from NPC conditioned medium 
suppressed the ability of glioma stem cells to initiate tumors from 100 
intracerebrally inoculated cells. 
7.2. Glioma Stem Cells respond to NPC-derived BMP7 
Further I showed that glioma stem cells expresses BMP receptors for both type I 
and II and showed that they strongly respond to NPC-derived BMP7 as detected in 
the form of phosphorylated smad1/5/8 signalling and also analysed the 
transcriptional changes in the expression of targeted genes like Id1 and Id2 which 
are strongly upregulated upon treatment with NPC conditioned medium. Pre-
treatment of GSCs with rBMP7 prior to brain-injection into mice strongly 
enhanced survival, as compared to controls receiving untreated GSCs.  
7.3. NPC derived BMP7 elicits a pro-differentiation effect on glioma stem 
cells 
BMP7 or NPC-derived BMP7 induced morphological changes in glioma stem cells 
like a more differentiated morphology.  I also observed an increase in the 
expression of astroglial markers (Glial fibrillary acidic protein (GFAP) 
immunoreactivity), together with a reduced stemness marker nestin which suggests 
that BMP7 from NPC produces a pro-differentiation action on glioma stem cells 
(which, predominantly, acquire an astroglial-like fate) and depletes the pool of 
tumorigenic glioma stem cells.  
Overall, my findings suggest that NPCs are attracted to glioma and that BMP7 
release from NPCs suppresses CD133+ glioma stem cells. Therefore, NPC-derived 
BMP7 might be a promising new strategy against malignant glioblastomas 
inducing differentiation rather than killing the tumor-initiating glioma stem cells. 
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II. Cell autonomous mechanism of ets transcription factor induced 
pro-tumorigenic signalling in glioma 
The pro-tumorigenic effects of ets transcription factors are long known (Dittmer 
and Nordheim, 1998) and especially the invasion promoting role of the founding 
member of the ets family ets1 has been described in glioma (Kita et al., 2001; 
Kitange et al., 1999a; Kitange et al., 1999b). However, it remained largely 
unexplored how ets factors promote glioma proliferation (Kitange et al., 1999a). In 
my present study I showed that ets factors can have profound effects on brain 
tumor progression by altering the redox levels in glioma via increased expression 
of TfR. 
Increased oxidant production in gliomas occured downstream of TfR 
overexpression and excess iron accumulation.  Increased oxidant (ROS) production 
in gliomas expressing TfR at high level inactivates the tumor suppressor LMW-
PTP, activates the MAPK and Akt pathways, inactivates cell cycle control at the 
G1 checkpoint and drives glioma proliferation in vitro and in vivo. Concomitantly, 
TfR mediated high glutamate release, making iron accumulating glioma cells 
excitotoxic for neurons. Overall, the data indicate that in glioma TfR co-ordinately 
promotes tumor growth and the provision of space for the advancing tumor. 
7.4. Transferrin receptor expression in glioma is regulated by an ets 
transcription factor 
I detected high levels of TfR expression in virtually all proliferating cells in my 
glioma model and observed that proliferation indeed largely depended on TfR 
expression in the human glioma cells (U373 cells). Under physiological conditions 
the expression of TfR is regulated in a complex fashion on the transcriptional ( 
Sieweke, M. H. et al, 1996, Marziali, G. et al, 2002) and post-transcriptional ( 
Owen, D. et al, 1987) level. However, in the U373 glioma cells, TfR expression 
remained largely unchanged after iron chelation or iron administration. This 
suggests that the diverse cellular iron regulatory mechanisms, which co-control 
TfR mRNA stability according to the intracellular iron level under physiological 
conditions ( Zecca, L. et al, 2004), have a minor role for TfR expression in glioma. 
Using a reporter gene assay I screened for factors exerting transcriptional control 
over TfR expression and observed that mainly ets factors are responsible for the 
elevated TfR levels in glioma. Furthermore, interfering with ets signalling strongly 
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attenuated TfR expression, which could be rescued to control levels by 
overexpressing TfR from a vector. Hif1 and hypoxia did not alter TfR expression 
in glioma.  
7.5. Transferrin receptors control redox signaling and proliferation 
Downregulation of TfR expression by attenuating ets activity decreased 
intracellular iron accumulation and decreased the redox level in glioma. The 
generation of reactive oxygen species is catalyzed by excess intracellular iron and 
contributes to brain pathology ( Zecca, L. et al, 2004) and high oxidant levels can 
promote cancer cell proliferation ( Hussain, S. P. et al, 2003). Proliferation of 
U373-etsDN cells was largely diminished compared to wild type cells, but could 
be fully rescued by forced TfR expression. Furthermore, the overexpression of TfR 
was sufficient to rescue clonal growth of etsDN cells. These data show for the first 
time, that modulation of redox signalling is an important pro-tumorigenic effect of 
ets transcription factors.  
7.6. LMW-PTP is a target of TfR-mediated redox signaling 
Next, I asked which molecule(s) and signalling pathways may be specifically 
altered by elevated oxidant levels in glioma and identified LMW-PTP as a target of 
ROS in brain tumor cells. I showed that oxidised LMW-PTP was much more 
abundant in cells expressing TfR at high level than in U373etsDN cells containing 
TfR only at low level. Forced expression of a point mutated (inactive) form of 
LMW-PTP rescued U373etsDN cell growth, showing the importance of the 
oxidisation (inactivation) of this molecule for glioma proliferation.   
 
LMW-PTP is an important negative modulator of receptor tyrosine kinases like the 
PDGF-receptor (Tonks, 2006) and counteracts activation of the Ras/MAPK and 
PI3Kinase/Akt signalling pathways downstream of growth factor signalling 
(Giannoni et al., 2006; Pandey et al., 2007; Xing et al., 2007). In this  part of thesis 
I provided evidence that the MAPK and Akt pathways are only fully active in 
gliomas with high TfR expression. In U373etsDN cells the low TfR expression 
induces only low iron accumulation that generates only low oxidant levels, which 
oxidises little LMW-PTP. Therefore, in U373etsDN cells the LMW-PTP can be 
active and yields low MAPK and Akt activation. Simple re-expression of TfR in 
U373etsDN gliomas fully reverts this phenotype. Elevated Akt and MAPK 
signalling is found in most glioma and may be one of the primary parthways 
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driving brain tumor initiation and progression (Holland, 2001). This study suggests 
that TfR mediated redox signalling is in addition to mutations of growth factor 
receptors and of PTEN - important for the activation of Akt and MAPK. 
7.7. TfR expression triggers Akt and MAPK signaling and inhibits p21 
and pRB 
Akt and MAPKs exert growth control by inactivation of G1 checkpoint proteins 
p21 and pRB ( Zhou, B.P. et al, 2001, Suyama, H. et al, 2004, Fernandes, D. J. et 
al, 2004). In glioma cells with high redox signalling (U373WT and 
U373etsDN+TfR cells) I observed hyperphosphorylated (inactivated) pRB, 
whereas U373etsDN cells contained hypophosporylated pRB, which actively 
blocks cell cycle entry in G1. Likewise, cells with high TfR Expression and 
activated Akt showed inactivation of the G1 cell cycle arrest protein p21. The 
tumor suppressor p21 is phosphorylated by Akt, which induces shuffling of p21 
out of the nucleus and loss of tumor suppressor function ( Zhou, B. P. et al, 2001). 
I observed high nuclear p21 in U373etsDN cells and high cytoplasmic p21 in 
U373WT and U373etsDN+TfR cells.  On the contrary, the TfR-low cells (U373-
etsDN) were arrested in G1 and in G2.  
 
High activity of the MAPK pathway is not only important for checkpoint control, 
but can also signal to ets transcription factors, which are the nuclear effectors for 
many MAPK signals (Dittmer and Nordheim, 1998; Sharrocks, 2001). 
Consequently, I found that TfR overexpression in etsDN cells facilitated massive 
overexpression of a range of cancer-relevant ets factors. This level of ets 
overexpression appeared specifically in glioma also expressing the dominant 
negative ets construct plus TfR (i.e. U373etsDN+TfR cells), since only here a 
block in ets transcription needed to be overcome. Cells expressing etsDN alone 
(i.e. U373etsDN) had no means to overexpress ets factor. The expression of TfR 
was modulated by inducing changes in oxidant levels after application of H2O2 and 
NAC. In our model TfR appears to be downstream of ets factors and the expression 
of ets factors can also be redox dependent (Wilson et al., 2005). Hence, there is a 
possibility that ets mediated TfR expression increases oxidants that finally induce 
ets factors again. The increased cell cycle arrest in TfR-low cells explains the 
results from our BrdU assay, which showed that U373etsDN cells proliferate less 
than U373WT and U373etsDN+TfR cells. 
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7.8. TfR-mediated redox signaling accelerates glioma growth in vivo 
To see if glioma growth is also redox dependent in vivo, I measured subcutaneous 
growth of our human glioma lines in immune-compromised mice. Indeed, tumors 
were growing at much higher pace in glioma expressing TfR at high level. 
Systemic abrogation of high iron and ROS levels by applying an iron chelator or 
an anti-oxidant yielded reduced tumor growth, further indicating the relevance of 
redox signalling for glioma progression.  
7.9. TfR expression in glioma cells induces glutamate secretion and 
NMDA-receptor-mediated reduction of neuron mass 
Accelerated proliferation rates in glioma could not lead to continous glioma 
progression without coordinated provision of space for the expanding tumor mass. 
On this point, glioma have requirements different from other solid tumors, since 
the skull prevents the brain tissue to be invariably be pushed aside. Gliomas 
circumvent this problem by actively creating space for their own growth, i.e. by 
killing surrounding neurons (Takano, T. et al, 2001, Sontheimer, H. 2003). I show 
that TfR promotes both, excessive proliferation and massive reduction of neuron 
mass, which most likely reflects NMDA-receptor-mediated excitotoxicity. Overall, 
our data help to explain the long standing observation that iron promotes neural 
tumor cell cycles (Jeitner and Renton, 1996; Renton and Jeitner, 1996) and growth 
of glioma (Basset et al., 1985). Furthermore, this study suggests that the increased 
transferrin receptor expression (Recht et al., 1990) and the augmented iron 
accumulation (Mykhaylyk et al., 2005) which are reported especially for high 
grade glioma are not mere by-products of a disturbed metabolism, but are a driving 
force for tumor proliferation 
 
Hence, TfR represents an important target for glioma therapy, by which neural 
tumor cell cycles ( Renton, F. J. et al, 1996, Jeitner, T. M. et al, 1996), glioma 
expansion ( Basset, P. et al, 1985) and neurological problems - that are frequently 
occurring with these tumor – may be suppressed. 
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8. Summary 
8.1. Neural precursor cell-derived BMP7 inhibit the tumorigenic potential 
of glioma stem cells 
In the first part of my thesis I described the molecular mechanism of the anti-
tumorigenic effect of endogenous neural precursor cells against glioma. As from 
the recent findings from our group that endogenous neural precursor cells (NPC) 
are attracted to experimental brain tumors (gliomas) and induce tumor cell death 
(Glass, R. et al, 2005 and Walzlein, J.H. et al 2008). Here, I report that NPC exert 
an even more far-reaching anti-tumorigenic effect: NPC migrate to murine and 
primary-human CD133-positive glioma stem cells (GSC) and suppress GSC via 
BMP7 release.  
In vivo, I investigated BMP7 expression by immunohistochemistry and detected 
BMP7 in the tumor-margin, where it was located in PSA-NCAM-positive NPCs. 
Real-time PCR and ELISA of cultured cells revealed that BMP7 is most 
abundantly expressed in PSA-NCAM positive NPC. Constitutive BMP7 release 
from cultivated NPCs was detected by ELISA. FACS analysis indicated that 
recombinant BMP7 and NPC-conditioned medium significantly reduced the 
number of murine and human GSCs. This effect was seen in bulk glioma cultures 
and in GSC-enriched cultures. Compund-C (a specific BMP-receptor antagonist) 
fully blocked the effect of recombinant BMP7 and NPC-conditioned medium. 
Importantly, I found that BMP7 release from NPCs suppresses the stem cell 
functions of GSCs which suppressed proliferation and self-renewal capacity of 
GSCs there by reducing their tumor initiating ability.   
Further I showed that glioma stem cells expresses BMP receptors for both type I 
and II and showed that they strongly respond to NPC-derived BMP7 as detected in 
the form of phosphorylated smad1/5/8 signalling and also analysed the 
transcriptional changes in the expression of targeted genes like Id1 and Id2 which 
are strongly up-regulated upon treatment with NPC conditioned medium or with 
rBMP7. 
Pre-treatment of GSCs with NPC conditioned medium or rBMP7 prior to brain-
injection into mice strongly enhanced survival, as compared to controls receiving 
untreated GSCs.  
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Overall, these findings suggest that neural precursor cells are attracted to glioma 
and that NPC-derived BMP7 inhibit the tumorigenic potential of glioma stem cells. 
8.2. Transferrin-receptor-mediated iron accumulation controls 
proliferation and glutamate release in glioma cells 
In the second part of my study I investigated cell autonomous events in glioma that 
are important for tumor progression and described a mechanism for ets transcriptor 
factor induced pro-tumorigenic signalling in glioma. Role of  ets family 
transcription factors especially ets1- has been described in glioma (Kita et al., 
2001; Kitange et al., 1999a; Kitange et al., 1999b) and further the protumorigenic 
effects of ets transcription factors are long known (Dittmer and Nordheim, 1998). 
However, it remained largely unexplored how ets factors promote glioma 
proliferation (Kitange et al., 1999a). In my study I showed that ets factors can have 
profound effects on brain tumor progression by altering the redox levels in glioma 
via increased expression of TfR. Transferrin receptors (TfR) are overexpressed in 
brain tumors, but the pathological relevance has not been fully explored. Here, I 
provided evidence that TfR is an important downstream effector of ets 
transcription factors that promotes glioma proliferation and increases glioma-
evoked neuronal death. Increased oxidant production in glioma expressing TfR at 
high level inactivates the tumor suppressor LMW-PTP, activates the MAPK and 
Akt pathways, inactivates cell cycle control at the G1 checkpoint and drives glioma 
proliferation in vitro and in vivo. Furthermore, my data suggest that the elevated 
redox potential reciprocally promotes the expression of TfR, potentially creating a 
positive feedback mechanism in which high amounts of ROS and TfR perpetually 
induce each other and drive glioma proliferation (Fig.8). 
 
Overall, my results help to explain the long standing observation that iron 
promotes neural tumor cell cycles (Jeitner and Renton, 1996; Renton and Jeitner, 
1996) and growth of glioma (Basset et al., 1985). Furthermore, our study suggests 
that the increased transferrin receptor expression (Recht et al., 1990) and the 
augmented iron accumulation (Mykhaylyk et al., 2005) which are reported 
especially for high grade glioma  are not mere by-products of a disturbed 
metabolism, but are a driving force for tumor proliferation. Concomitantly, TfR 
mediated high glutamate release making iron accumulating glioma cells 
excitotoxic for neurons. Overall, the whole data indicate that in glioma that TfR 
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promotes glioma progression by two mechanisms, an increase in proliferation rate 
and glutamate production, the latter mechanism providing space for the 
progressing tumor mass.  
 
 
Fig.8. Schematic drawing summarising the findings from the part of Transferrin-receptor-
mediated iron accumulation controls proliferation and glutamate release in glioma cells.  Ets-
factors induce TfR expression, TfR activity increases the labile iron pool and catalyses reactive 
oxygen formation (ROS), ROS facilitates proto-oncogenic pathways (MAPK, Akt) and blunts 
tumor suppressor pathways (p21, pRB) leading to accelerated growth; simultaneously ROS enables 
glutamate synthesis and release which leads to neuronal loss, i.e. creates space for tumor expansion 
(details, see text).    
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10. Zusammenfassung 
 
10.1. Neuronale Stamm- und Vorläuferzellen sezernieren BMP7 und 
inhibieren damit die Tumorigenität von Gliomstammzellen. 
Im ersten Teil meiner Arbeit habe ich den molekularen Mechanismus beschrieben, 
mit dem  endogene neuronale Vorläuferzellen antitumorigen gegen 
Gliomstammzellen wirken. Unsere Forschungsgruppe hat in bereits 
veröffentlichten Arbeiten gezeigt, dass neuronale Vorläuferzellen zu 
experimentellen Gehirntumoren migrieren und Tumorzelltod induzieren können 
(Glass, R et al., 2005; Wälzlein, J.H. et al. 2008). In der nun vorliegenden Arbeit 
zeige ich, dass die neuronalen Vorläuferzellen nicht nur benefiziell gegen die 
Hauptpopulation der Tumorzellen wirken, sondern darüber hinaus auch die 
kleinere Population der sehr aggressiven Tumorstammzellen – mittels Sekretion 
von BMP7 – supprimieren.  
Per Immunhistochemie habe ich nachgewiesen, dass BMP7 in den 
tumorrandständigen neuronalen Vorläuferzellen exprimiert ist (hier vor Allem in 
den migrierenden PSA-NCAM-exprimierenden Vorläuferzellen). BMP7 mRNA 
Expression habe ich in Neurosphärenkulturen  nachgewiesen und konnte zudem 
zeigen, dass das BMP7-Protein vor Allem in den PSA-NCAM-positiven Zellen 
angereichert wird. Darüber hinaus wird BMP7 von  neuronalen Vorläufern in 
Zellkultur kontinuierlich sekretiert. Gliomstammzellen besitzen die Rezeptoren für 
BMPs und werden durch BMPs aus neuronalen Vorläufern zur Phosphorylierung 
eines BMP-spezifischen „second-messengers“ (smad1/5/8) angeregt. Die 
verschiedenen Gliomstammzellen, die ich in meinen Experimenten verwendete,  
reagieren auf BMPs aus neuronalen Vorläufern mit Zelldifferenzierung und einer 
Abnahme ihrer Tumorigenität. Insgesamt zeigt meine Arbeit, dass neuronale 
Vorläuferzellen die Pathogenität der Gliomstammzellen unterdrücken. 
10.2. Transferrin-Rezeptor vermittelter Eisentransport kontrolliert 
die Proliferation und die Glutamat-Sekretion von Gliomzellen 
Im zweiten Teil meiner Arbeit habe ich einen zellautonomen Mechanismus 
untersucht, der Gliomzellen in vitro und in vivo vermehrt expandieren lässt. Meine 
Ergebnisse zeigen, dass die Familie der ets-Transkriptionsfaktoren (und hier 
speziell ets1) Gliomzellen zur Proliferation anregen, indem sie die Expresion eines 
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Eisentransporters (dem Transferrin-Rezeptor-1; CD71) induzieren und damit die 
intrazelluläre Akkumulation von Eisenionen begünstigen. Eisenionen fungieren als 
Katalysatoren für die Bildung von Sauerstoffradikalen (Fenton-Reaktion) und 
verändern das zelluläre Redox-Gleichgewicht. Meine Daten beweisen, dass die 
Sauerstoffradikale aus der Fenton-Reaktion eine bestimmte Phosphatase inhibieren 
(LMW-PTP), woraufhin der MAP-Kinase Signaltransduktionsweg (und dadurch 
vermittelt auch der Zellzyklus) angeschaltet werden. Insgesamt proliferieren die 
Gliomzellen dadurch besser, zusätzlich hat dieser Mechanismus aber auch eine 
zweite wichtige pathogene Eigenschaft. Die Veränderung des Redox-
Gleichgewichts in den Gliomzellen (via ets1 und CD71 vermittelt) regt die Tumore 
zu verstärkter Sekretion von Glutamat an. Dadurch werden die Gliome sehr 
zytotoxisch und induzieren Zelltod in den Zellen des tumorumgebenden 
Parenchyms (vor Allem in Neuronen). Das untergegangene Nervengewebe schafft 
damit den Platz, den der Tumor zur Expansion braucht. (Da der Schädel das 
Gehirn auf allen Seiten begrenzt, muss der Tumor sich auf diese Art Platz 
schaffen). 
Insgesamt zeigt meine Arbeit, dass die ets1-induzierte CD71 Expression nicht nur 
das Tumorwachstum befördert, sondern (eng koordiniert mit dem 
Proliferationsprozess) auch den Platz zum Tumorwachstum schafft. 
 
Schlagworte: 
Glioma stem Zelle, BMP-7, Transferrin Rezeptor, Ets, Reactive oxygen spezies.
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